Citations Database Search Results

Download these results to MS Excel

455 records found for:
Title = Hepatitis C
Year =

1. Mezzacappa C, Kim NJ, Vutien P, Kaplan DE, Ioannou GN, Taddei TH. Screening for Hepatocellular Carcinoma and Survival in Patients With Cirrhosis After Hepatitis C Virus Cure. JAMA Network Open. 2024 Jul 1; 7(7):e2420963.
2. Talal AH, Markatou M, Liu A, Perumalswami PV, Dinani AM, Tobin JN, Brown LS. Integrated Hepatitis C-Opioid Use Disorder Care Through Facilitated Telemedicine: A Randomized Trial. JAMA. 2024 Apr 23; 331(16):1369-1378.
3. Chen PH, Truong J, Kawamoto J, Bhattacharya D, Patel A. Outcomes and Barriers Associated with Telehealth-Based Hepatitis C Treatment During Early Phases of the COVID-19 Pandemic. Federal practitioner : for the health care professionals of the VA, DoD, and PHS. 2024 Mar 1; 41(3):88-92.
4. Tsui JI, Gojic AJ, Pierce KA, Tung EL, Connolly NC, Radick AC, Hunt RR, Sandvold R, Taber K, Ninburg M, Kubiniec RH, Scott JD, Hansen RN, Stekler JD, Austin EJ, Williams EC, Glick SN. Pilot study of a community pharmacist led program to treat hepatitis C virus among people who inject drugs. Drug and Alcohol Dependence Reports. 2024 Mar 1; 10:100213.
5. Liang X, Justice AC, Marconi VC, Aouizerat BE, Xu K. Co-occurrence of injection drug use and hepatitis C increases epigenetic age acceleration that contributes to all-cause mortality among people living with HIV. Epigenetics. 2023 Dec 1; 18(1):2212235.
6. Mohtashemi NZ, Teng CY, Benhammou J, Dong T, Goetz MB, Patel A, Kawamoto J, Bhattacharya D. Evaluation of and implications for a novel hepatitis C e-consult direct-to-treatment pilot program. Scientific reports. 2023 Oct 11; 13(1):17241.
7. Cartwright EJ, Pierret C, Minassian C, Esserman DA, Tate JP, Goetz MB, Bhattacharya D, Fiellin DA, Justice AC, Lo Re V, Rentsch CT. Alcohol Use and Sustained Virologic Response to Hepatitis C Virus Direct-Acting Antiviral Therapy. JAMA Network Open. 2023 Sep 5; 6(9):e2335715.
8. Chhatwal J, Hajjar A, Mueller PP, Nemutlu G, Kulkarni N, Peters MLB, Kanwal F. Hepatocellular Carcinoma Incidence Threshold for Surveillance in Virologically Cured Hepatitis C Individuals. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2023 Jun 9; s1542-3565.
9. Ahrens K, Sharbaugh M, Jarlenski MP, Tang L, Allen L, Austin AE, Barnes AJ, Burns ME, Clark S, Zivin K, Mack A, Liu G, Mohamoud S, McDuffie MJ, Hammerslag L, Gordon AJ, Donohue JM, Writing Committee for Medicaid Outcomes Distributed Research Network. Prevalence of Testing for Human Immunodeficiency Virus, Hepatitis B Virus, and Hepatitis C Virus Among Medicaid Enrollees Treated With Medications for Opioid Use Disorder in 11 States, 2016-2019. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2023 May 24; 76(10):1793-1801.
10. Yakovchenko V, Jacob DA, Rogal SS, Morgan TR, Rozenberg-Ben-Dror K. User experience of a hepatitis c population management dashboard in the Department of Veterans Affairs. PLoS ONE. 2023 May 2; 18(5):e0285044.
11. Jacob JS, Shaikh A, Goli K, Rich NE, Benhammou JN, Ahmed A, Kim D, Rana A, Goss JA, Naggie S, Lee TH, Kanwal F, Cholankeril G. Improved Survival After Liver Transplantation for Patients With Human Immunodeficiency Virus (HIV) and HIV/Hepatitis C Virus Coinfection in the Integrase Strand Transfer Inhibitor and Direct-Acting Antiviral Eras. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2023 Feb 18; 76(4):592-599.
12. Hill DD, Kramer JR, Chaffin KR, Mast TC, Robertson MN, Kanwal F, Haber BA. Effectiveness of elbasvir/grazoprevir plus ribavirin for hepatitis C virus genotype 1a infection and baseline NS5A resistance. Annals of hepatology. 2023 Jan 8; 28(2):100899.
13. Haque LY, Fiellin DA, Tate JP, Esserman D, Bhattacharya D, Butt AA, Crystal S, Edelman EJ, Gordon AJ, Lim JK, Tetrault JM, Williams EC, Bryant K, Cartwright EJ, Rentsch CT, Justice AC, Lo Re V, McGinnis KA. Association Between Alcohol Use Disorder and Receipt of Direct-Acting Antiviral Hepatitis C Virus Treatment. JAMA Network Open. 2022 Dec 1; 5(12):e2246604.
14. Barry MP, Austin EJ, Bhatraju EP, Glick SN, Stekler JD, Tung EL, Hansen RN, Williams EC, Gojic AJ, Pickering EI, Tsui JI. Qualitative inquiry into perceptions of HIV pre-exposure prophylaxis among people who inject drugs living with hepatitis C in Seattle, WA, USA. Harm reduction journal. 2022 Nov 1; 19(1):121.
15. Kramer JR, Cao Y, Li L, Smith D, Chhatwal J, El-Serag HB, Kanwal F. Longitudinal Associations of Risk Factors and Hepatocellular Carcinoma in Patients With Cured Hepatitis C Virus Infection. The American journal of gastroenterology. 2022 Nov 1; 117(11):1834-1844.
16. Conti J, Dryden E, Fincke BG, Dunlap S, McInnes DK. Innovative Approaches to Engaging Homeless and Marginally Housed Patients in Care: a Case Study of Hepatitis C. Journal of general internal medicine. 2023 Jan 1; 38(1):156-164.
17. Clements KM, Kunte PS, Clark MA, Gurewich D, Greenwood BC, Sefton L, Pratt C, Person SD, Wessolossky MA. Uptake of hepatitis C virus treatment in a multi-state Medicaid population, 2013-2017. Health services research. 2022 Dec 1; 57(6):1312-1320.
18. Lymberopoulos P, Shaikh A, Rich NE, Benhammou JN, Kanwal F, Cholankeril G. Comparable Survival for Hepatitis C-Related Hepatocellular Carcinoma After Liver Transplantation Irrespective of Viremic Status. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2023 May 1; 21(5):1362-1364.e1.
19. Oselio B, Singal AG, Zhang X, Van T, Liu B, Zhu J, Waljee AK. Reinforcement learning evaluation of treatment policies for patients with hepatitis C virus. BMC medical informatics and decision making. 2022 Mar 11; 22(1):63.
20. Mueller PP, Chen Q, Ayer T, Nemutlu GS, Hajjar A, Bethea ED, Peters MLB, Lee BP, Janjua NZ, Kanwal F, Chhatwal J. Duration and cost-effectiveness of hepatocellular carcinoma surveillance in hepatitis C patients after viral eradication. Journal of Hepatology. 2022 Jul 1; 77(1):55-62.
21. Kramer JR, Puenpatom A, Cao Y, Yu X, El-Serag HB, Kanwal F. Treatment of hepatitis C virus infection in people with opioid use disorder: a real-world study of elbasvir/grazoprevir in a US Department of Veterans Affairs population. The American journal of drug and alcohol abuse. 2022 Jul 4; 48(4):445-453.
22. Yakovchenko V, Morgan TR, Chinman MJ, Powell BJ, Gonzalez R, Park A, Malone PS, Chartier M, Ross D, Rogal SS. Mapping the road to elimination: a 5-year evaluation of implementation strategies associated with hepatitis C treatment in the veterans health administration. BMC health services research. 2021 Dec 18; 21(1):1348.
23. Beste LA, Zhang X, Su GL, Van T, Ioannou GN, Oselio B, Tincopa M, Liu B, Singal AG, Zhu J, Waljee AK. Adapted time-varying covariates Cox model for predicting future cirrhosis development performs well in a large hepatitis C cohort. BMC medical informatics and decision making. 2021 Dec 14; 21(1):347.
24. Austin EJ, Tsui JI, Barry MP, Tung E, Glick SN, Ninburg M, Williams EC. Health care-seeking experiences for people who inject drugs with hepatitis C: Qualitative explorations of stigma. Journal of substance abuse treatment. 2022 Jun 1; 137:108684.
25. D'Ambrosio R, Ioannou GN. Hepatocellular Carcinoma Risk, Outcomes, and Screening After Hepatitis C Eradication. Hepatology communications. 2021 Sep 1; 5(9):1465-1468.
26. Auty SG, Shafer PR, Dusetzina SB, Griffith KN. Association of Medicaid Managed Care Drug Carve Outs With Hepatitis C Virus Prescription Use. JAMA health forum. 2021 Aug 27; 2(8):e212285.
27. Auty SG, Shafer PR, Griffith KN. Medicaid Subscription-Based Payment Models and Implications for Access to Hepatitis C Medications. JAMA health forum. 2021 Aug 27; 2(8):e212291.
28. Raasikh T, Jamali T, Flores A, Cotton RT, Ramanathan V, Tan HP, Hernaez R. Systematic review: hepatitis C viraemic allografts to hepatitis C-negative recipients in solid organ transplantation. Alimentary pharmacology & therapeutics. 2021 Sep 1; 54(5):571-582.
29. Nyamathi AM, Wall SA, Yadav K, Shin SS, Chang A, Arce N, Cuellar H, Fernando S, White K, Gelberg L, Salem BE. Engaging the Community in Designing a Hepatitis C Virus Treatment Program for Adults Experiencing Homelessness. Qualitative Health Research. 2021 Sep 1; 31(11):2069-2083.
30. Ismail MS, Mohamed I, Polychronopoulou E, Goss JA, Kuo YF, Kanwal F, Jalal PK. Outcomes in the Era of Interferon-Free Direct-Acting Antiviral Therapy After Liver Transplantation in Patients with Hepatitis C Virus and Hepatocellular Carcinoma. Journal of hepatocellular carcinoma. 2021 Jun 29; 8:701-711.
31. McInnes DK, Troszak LK, Fincke BG, Shwartz M, Midboe AM, Gifford AL, Dunlap S, Byrne T. Is the Availability of Direct-Acting Antivirals Associated with Increased Access to Hepatitis C Treatment for Homeless and Unstably Housed Veterans? Journal of general internal medicine. 2022 Apr 1; 37(5):1038-1044.
32. Desai N, Rich NE, Jain MK, Blackwell JM, Murphy CC, Perryman P, McBryde J, Quirk L, Clark C, Villarreal D, Waljee AK, Gopal P, Singal AG. Randomized Clinical Trial of Inreach With or Without Mailed Outreach to Promote Hepatitis C Screening in a Difficult-to-Reach Patient Population. The American journal of gastroenterology. 2021 May 1; 116(5):976-983.
33. Su F, Cogan CJ, Bendich I, Zhang N, Whooley MA, Kuo AC. Hepatitis C infection and complication rates after total shoulder arthroplasty in United States veterans. JSES international. 2021 Jul 1; 5(4):699-706.
34. Celli R, Saffo S, Kamili S, Wiese N, Hayden T, Taddei T, Jain D. Liver Pathologic Changes After Direct-Acting Antiviral Agent Therapy and Sustained Virologic Response in the Setting of Chronic Hepatitis C Virus Infection. Archives of pathology & laboratory medicine. 2021 Apr 1; 145(4):419-427.
35. Tse CS, Yang JD, Mousa OY, Nelson KM, Pungpapong S, Keaveny A, Aqel BA, Vargas H, Dickson RC, Watt K, Gores GJ, Roberts LR, Leise MD. Direct-Acting Antiviral Therapy in Liver Transplant Patients With Hepatocellular Carcinoma and Hepatitis C. Transplantation direct. 2021 Jan 1; 7(1):e635.
36. Weinheimer-Haus EM, Yu X, Singal AG, Naylor KB, Ammori C, Coyle J, Nallamothu BK, Witala W, Zhu J, Waljee AK. Utilizing public health data to geotarget hepatitis C virus elimination approaches in urban and rural Michigan. Journal of Viral Hepatitis. 2021 Feb 1; 28(2):440-444.
37. Chen Q, Ayer T, Adee MG, Wang X, Kanwal F, Chhatwal J. Assessment of Incidence of and Surveillance Burden for Hepatocellular Carcinoma Among Patients With Hepatitis C in the Era of Direct-Acting Antiviral Agents. JAMA Network Open. 2020 Nov 2; 3(11):e2021173.
38. Ismail MS, Hassan M, Khaderi SA, Yousry WA, Kamal El-Din MM, Bahaa El-Din MM, El Sayed OA, Kaseb AO, Goss JA, Kanwal F, Jalal PK. Clinical efficacy of direct-acting antiviral therapy for recurrent hepatitis C virus infection after liver transplantation in patients with hepatocellular carcinoma. World journal of hepatology. 2020 Sep 27; 12(9):628-640.
39. Vutien P, Kim NJ, Moon AM, Pearson M, Su F, Berry K, Gelman H, Ioannou GN. Fibroscan liver stiffness after anti-viral treatment for hepatitis C is independently associated with adverse outcomes. Alimentary pharmacology & therapeutics. 2020 Dec 1; 52(11-12):1717-1727.
40. Yakovchenko V, DeSotto K, Drainoni ML, Lukesh W, Miller DR, Park A, Shao Q, Thornton DJ, Gifford AL. Using Lean-Facilitation to Improve Quality of Hepatitis C Testing in Primary Care. Journal of general internal medicine. 2021 Feb 1; 36(2):349-357.
41. Beste LA, Green P, Berry K, Belperio P, Ioannou GN. Hepatitis C-Related Hepatocellular Carcinoma Incidence in the Veterans Health Administration After Introduction of Direct-Acting Antivirals. JAMA. 2020 Sep 8; 324(10):1003-1005.
42. Ioannou GN, Tang W, Beste LA, Tincopa MA, Su GL, Van T, Tapper EB, Singal AG, Zhu J, Waljee AK. Assessment of a Deep Learning Model to Predict Hepatocellular Carcinoma in Patients With Hepatitis C Cirrhosis. JAMA Network Open. 2020 Sep 1; 3(9):e2015626.
43. Reader SW, Kim HS, El-Serag HB, Thrift AP. Persistent Challenges in the Hepatitis C Virus Care Continuum for Patients in a Central Texas Public Health System. Open forum infectious diseases. 2020 Aug 1; 7(8):ofaa322.
44. Shakeri A, Srimurugathasan N, Suda KJ, Gomes T, Tadrous M. Spending on Hepatitis C Antivirals in the United States and Canada, 2014 to 2018. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 2020 Sep 1; 23(9):1137-1141.
45. Benhammou JN, Moon AM, Pisegna JR, Su F, Vutien P, Moylan CA, Ioannou GN. Nonalcoholic Fatty Liver Disease Risk Factors Affect Liver-Related Outcomes After Direct-Acting Antiviral Treatment for Hepatitis C. Digestive diseases and sciences. 2021 Jul 1; 66(7):2394-2406.
46. Kim HS, Guerrero R, Reader SW, Daheri M, Balakrishnan M, Troisi CL, El-Serag HB, Thrift AP. Low Yield of Hepatitis C Infection in an Outreach Screening Program in Harris County, Texas. Open forum infectious diseases. 2020 Jul 1; 7(7):ofaa191.
47. Francis AK, Beaudoin FL, Naidjate SS, Berard-Collins C, Zullo AR. Comparing Treatment Response Between Older and Younger Patients with Chronic Hepatitis C Virus Infection on Direct-acting Antiviral Agents. Rhode Island medical journal (2013). 2020 Jun 1; 103(5):35-40.
48. Singal AG, Lim JK, Kanwal F. AGA Clinical Practice Update on Interaction Between Oral Direct-Acting Antivirals for Chronic Hepatitis C Infection and Hepatocellular Carcinoma: Expert Review. Clinical liver disease. 2020 Jun 1; 15(6):211-212.
49. Waljee AK, Ryan KA, Krenz CD, Ioannou GN, Beste LA, Tincopa MA, Saini SD, Su GL, Arasim ME, Roman PT, Nallamothu BK, De Vries R. Eliciting patient views on the allocation of limited healthcare resources: a deliberation on hepatitis C treatment in the Veterans Health Administration. BMC health services research. 2020 May 1; 20(1):369.
50. Yakovchenko V, Miech EJ, Chinman MJ, Chartier M, Gonzalez R, Kirchner JE, Morgan TR, Park A, Powell BJ, Proctor EK, Ross D, Waltz TJ, Rogal SS. Strategy Configurations Directly Linked to Higher Hepatitis C Virus Treatment Starts: An Applied Use of Configurational Comparative Methods. Medical care. 2020 May 1; 58(5):e31-e38.
51. Do A, Esserman DA, Krishnan S, Lim JK, Taddei TH, Hauser RG, Tate JP, Re VL, Justice AC. Excess Weight Gain After Cure of Hepatitis C Infection with Direct-Acting Antivirals. Journal of general internal medicine. 2020 Jul 1; 35(7):2025-2034.
52. Gifford AL. Sutton's Law, Substance Use Disorder, and Treatment of Hepatitis C in the Era of Direct-acting Antivirals. Journal of general internal medicine. 2020 Apr 1; 35(4):988-989.
53. US Preventive Services Task Force , Owens DK, Davidson KW, Krist AH, Barry MJ, Cabana M, Caughey AB, Donahue K, Doubeni CA, Epling JW, Kubik M, Ogedegbe G, Pbert L, Silverstein M, Simon MA, Tseng CW, Wong JB. Screening for Hepatitis C Virus Infection in Adolescents and Adults: US Preventive Services Task Force Recommendation Statement. JAMA. 2020 Mar 10; 323(10):970-975.
54. Higashi RT, Jain MK, Quirk L, Rich NE, Waljee AK, Turner BJ, Lee SC, Singal AG. Patient and provider-level barriers to hepatitis C screening and linkage to care: A mixed-methods evaluation. Journal of Viral Hepatitis. 2020 Jul 1; 27(7):680-689.
55. So-Armah KA, Lim JK, Lo Re V, Tate JP, Chang CH, Butt AA, Gibert CL, Rimland D, Marconi VC, Goetz MB, Ramachandran V, Brittain E, Long M, Nguyen KL, Rodriguez-Barradas MC, Budoff MJ, Tindle HA, Samet JH, Justice AC, Freiberg MS, VACS Project Team. FIB-4 stage of liver fibrosis is associated with incident heart failure with preserved, but not reduced, ejection fraction among people with and without HIV or hepatitis C. Progress in Cardiovascular Diseases. 2020 Mar 1; 63(2):184-191.
56. Zou B, Yeo YH, Le MH, Henry L, Chang ET, Lok AS, Cheung R, Nguyen MH. Prevalence of Viremic Hepatitis C Virus Infection by Age, Race/Ethnicity, and Birthplace and Disease Awareness Among Viremic Persons in the United States, 1999-2016. The Journal of Infectious Diseases. 2020 Jan 14; 221(3):408-418.
57. Kim NJ, Pearson M, Vutien P, Su F, Moon AM, Berry K, Green PK, Williams EC, Ioannou GN. Alcohol Use and Long-Term Outcomes Among U.S. Veterans Who Received Direct-Acting Antivirals for Hepatitis C Treatment. Hepatology communications. 2020 Feb 1; 4(2):314-324.
58. Choi DT, Puenpatom A, Yu X, Erickson KF, Kanwal F, El-Serag HB, Kramer JR. Effectiveness of Elbasvir/Grazoprevir in patients with hepatitis C virus genotype 1 infection and chronic kidney disease in the United States veterans population. Antiviral research. 2020 Feb 1; 174:104698.
59. Fuster D, Gelberg L. Community Screening, Identification, and Referral to Primary Care, for Hepatitis C, B, and HIV Among Homeless Persons in Los Angeles. Journal of community health. 2019 Dec 1; 44(6):1044-1054.
60. Moon AM, Green PK, Rockey DC, Berry K, Ioannou GN. Hepatitis C eradication with direct-acting anti-virals reduces the risk of variceal bleeding. Alimentary pharmacology & therapeutics. 2020 Feb 1; 51(3):364-373.
61. Huang CF, Iio E, Jun DW, Ogawa E, Toyoda H, Hsu YC, Haga H, Iwane S, Enomoto M, Lee DH, Wong G, Liu CH, Tada T, Chuang WL, Cheung R, Hayashi J, Tseng CH, Yasuda S, Tran S, Kam L, Henry L, Jeong JY, Nomura H, Park SH, Nakamuta M, Huang JF, Tai CM, Lo GH, Lee MH, Yang HI, Kao JH, Tamori A, Eguchi Y, Ueno Y, Furusyo N, Tanaka Y, Yu ML, Nguyen MH, REAL-C Investigators. Direct-acting antivirals in East Asian hepatitis C patients: real-world experience from the REAL-C Consortium. Hepatology international. 2019 Sep 1; 13(5):587-598.
62. Uyei J, Taddei TH, Kaplan DE, Chapko M, Stevens ER, Braithwaite RS. Setting ambitious targets for surveillance and treatment rates among patients with hepatitis C related cirrhosis impacts the cost-effectiveness of hepatocellular cancer surveillance and substantially increases life expectancy: A modeling study. PLoS ONE. 2019 Aug 26; 14(8):e0221614.
63. Gidwani-Marszowski R, Owens DK, Lo J, Goldhaber-Fiebert JD, Asch SM, Barnett PG. The Costs of Hepatitis C by Liver Disease Stage: Estimates from the Veterans Health Administration. Applied Health Economics and Health Policy. 2019 Aug 1; 17(4):513-521.
64. Singal AG, Rich NE, Mehta N, Branch AD, Pillai A, Hoteit M, Volk M, Odewole M, Scaglione S, Guy J, Said A, Feld JJ, John BV, Frenette C, Mantry P, Rangnekar AS, Oloruntoba O, Leise M, Jou JH, Bhamidimarri KR, Kulik L, Ioannou GN, Huang A, Tran T, Samant H, Dhanasekaran R, Duarte-Rojo A, Salgia R, Eswaran S, Jalal P, Flores A, Satapathy SK, Kagan S, Gopal P, Wong R, Parikh ND, Murphy CC. Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection Is Associated With Increased Survival in Patients With a History of Hepatocellular Carcinoma. Gastroenterology. 2019 Nov 1; 157(5):1253-1263.e2.
65. Hanberg JS, Freiberg MS, Goetz MB, Rodriguez-Barradas MC, Gibert C, Oursler KA, Justice AC, Tate JP, VACS Project Team. Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Inflammatory Biomarkers in Human Immunodeficiency Virus (HIV), Hepatitis C Virus (HCV), and HIV/HCV Coinfection. Open forum infectious diseases. 2019 Oct 1; 6(10):ofz347.
66. Zullig LL, Bhatia HL, Gellad ZF, Eatherly M, Henderson R, Bosworth HB. Adoption of direct-acting antiviral medications for hepatitis C: a retrospective observational study. BMC health services research. 2019 Jul 25; 19(1):521.
67. Kellogg JB, Lee JD, Murphy D, Arya M. mHealth Can Activate Patients to Discuss Hepatitis C Screening with Physicians. Journal of mobile technology in medicine. 2019 Jul 23; 8(1):20-28.
68. Shaikh OS, Rogal S, Malik A, Sharma V, Cacciarelli T. Liver Transplant From Increased-Risk Donors in the Era of Direct-Acting Antivirals for Hepatitis C. Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation. 2020 Oct 1; 18(5):605-611.
69. Chen Q, Ayer T, Bethea E, Kanwal F, Wang X, Roberts M, Zhuo Y, Fagiuoli S, Petersen J, Chhatwal J. Changes in hepatitis C burden and treatment trends in Europe during the era of direct-acting antivirals: a modelling study. BMJ open. 2019 Jun 11; 9(6):e026726.
70. Beste LA. Concerns About Direct-Acting Antiviral Agents for Hepatitis C-Cause for Reassurance. JAMA Network Open. 2019 Jun 5; 2(6):e194757.
71. Bakr O, Gelberg L, Seragaki S, Youn S, Kawamoto J, Hoppe M, Altman L, Kopelson K, May FP, Cowan B, Bhattacharya D. Treating Hepatitis C in Homeless Veterans at the Greater Los Angeles Veterans' Affairs Medical Center. Hepatology (Baltimore, Md.). 2019 Sep 1; 70(3):1071-1073.
72. Fisk RJ, Kumar D, Kellogg JB, Murphy DR, Staggers KA, Arya M. A Proof of Concept Study Demonstrating the Feasibility of a Text Message Prompt for Hepatitis C Testing in the 1945-1965 Birth Cohort. Cureus. 2019 May 24; 11(5):e4745.
73. Chhatwal J, Chen Q, Bethea ED, Hur C, Spaulding AC, Kanwal F. The impact of direct-acting anti-virals on the hepatitis C care cascade: identifying progress and gaps towards hepatitis C elimination in the United States. Alimentary pharmacology & therapeutics. 2019 Jul 1; 50(1):66-74.
74. Ji F, Yeo YH, Wei MT, Ogawa E, Enomoto M, Lee DH, Iio E, Lubel J, Wang W, Wei B, Ide T, Preda CM, Conti F, Minami T, Bielen R, Sezaki H, Barone M, Kolly P, Chu PS, Virlogeux V, Eurich D, Henry L, Bass MB, Kanai T, Dang S, Li Z, Dufour JF, Zoulim F, Andreone P, Cheung RC, Tanaka Y, Furusyo N, Toyoda H, Tamori A, Nguyen MH. Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis. Journal of Hepatology. 2019 Sep 1; 71(3):473-485.
75. Chhatwal J, Chen Q, Wang X, Ayer T, Zhuo Y, Janjua NZ, Kanwal F. Assessment of the Feasibility and Cost of Hepatitis C Elimination in Pakistan. JAMA Network Open. 2019 May 3; 2(5):e193613.
76. Zou WY, Choi K, Kramer JR, Yu X, Cao Y, El-Serag HB, Kanwal F. Risk of Hepatocellular Cancer Recurrence in Hepatitis C Virus+ Patients Treated with Direct-Acting Antiviral Agents. Digestive diseases and sciences. 2019 Nov 1; 64(11):3328-3336.
77. Voils CI, King HA, Thorpe CT, Blalock DV, Kronish IM, Reeve BB, Boatright C, Gellad ZF. Content Validity and Reliability of a Self-Report Measure of Medication Nonadherence in Hepatitis C Treatment. Digestive diseases and sciences. 2019 Oct 1; 64(10):2784-2797.
78. Yakovchenko V, Bolton RE, Drainoni ML, Gifford AL. Primary care provider perceptions and experiences of implementing hepatitis C virus birth cohort testing: a qualitative formative evaluation. BMC health services research. 2019 Apr 23; 19(1):236.
79. Rogal SS, Yakovchenko V, Waltz TJ, Powell BJ, Gonzalez R, Park A, Chartier M, Ross D, Morgan TR, Kirchner JE, Proctor EK, Chinman MJ. Longitudinal assessment of the association between implementation strategy use and the uptake of hepatitis C treatment: Year 2. Implementation science : IS. 2019 Apr 8; 14(1):36.
80. El-Serag HB, Christie IC, Puenpatom A, Castillo D, Kanwal F, Kramer JR. The effects of sustained virological response to direct-acting anti-viral therapy on the risk of extrahepatic manifestations of hepatitis C infection. Alimentary pharmacology & therapeutics. 2019 Jun 1; 49(11):1442-1447.
81. Njei B, Esserman D, Krishnan S, Ohl M, Tate JP, Hauser RG, Taddei T, Lim J, Justice AC. Regional and Rural-Urban Differences in the Use of Direct-acting Antiviral Agents for Hepatitis C Virus: The Veteran Birth Cohort. Medical care. 2019 Apr 1; 57(4):279-285.
82. Patel K, Zickmund SL, Jones H, Reid A, Calgaro L, Otero A, Coppler T, Rogal SS. Determinants of Hepatitis C Treatment Adherence and Treatment Completion Among Veterans in the Direct Acting Antiviral Era. Digestive diseases and sciences. 2019 Oct 1; 64(10):3001-3012.
83. Singal AG, Lim JK, Kanwal F. AGA Clinical Practice Update on Interaction Between Oral Direct-Acting Antivirals for Chronic Hepatitis C Infection and Hepatocellular Carcinoma: Expert Review. Gastroenterology. 2019 Jun 1; 156(8):2149-2157.
84. Woodward EN, Matthieu MM, Uchendu US, Rogal S, Kirchner JE. The health equity implementation framework: proposal and preliminary study of hepatitis C virus treatment. Implementation science : IS. 2019 Mar 12; 14(1):26.
85. Kumthekar A, Shull S, Lovejoy TI, Morasco BJ, Chang M, Barton J. Impact of hepatitis C treatment on pain intensity, prescription opioid use and arthritis. International journal of rheumatic diseases. 2019 Apr 1; 22(4):592-598.
86. Rentsch CT, Tate JP, Steel T, Butt AA, Gibert CL, Huang L, Pisani M, Soo Hoo GW, Crystal S, Rodriguez-Barradas MC, Brown ST, Freiberg MS, Graber CJ, Kim JW, Rimland D, Justice AC, Fiellin DA, Crothers KA, Akgün KM. Medical Intensive Care Unit Admission Among Patients With and Without HIV, Hepatitis C Virus, and Alcohol-Related Diagnoses in the United States: A National, Retrospective Cohort Study, 1997-2014. Journal of acquired immune deficiency syndromes (1999). 2019 Feb 1; 80(2):145-151.
87. Skolnik AA, Noska A, Yakovchenko V, Tsai J, Jones N, Gifford AL, McInnes DK. Experiences with interferon-free hepatitis C therapies: addressing barriers to adherence and optimizing treatment outcomes. BMC health services research. 2019 Feb 1; 19(1):91.
88. Byrne T, Troszak L, Midboe AM, Fincke BG, Shwartz M, Gifford AL, McInnes DK. A Novel Measure to Assess Variation in Hepatitis C Prevalence Among Homeless and Unstably Housed Veterans, 2011-2016. Public health reports (Washington, D.C. : 1974). 2019 Mar 1; 134(2):126-131.
89. Konerman MA, Beste LA, Van T, Liu B, Zhang X, Zhu J, Saini SD, Su GL, Nallamothu BK, Ioannou GN, Waljee AK. Machine learning models to predict disease progression among veterans with hepatitis C virus. PLoS ONE. 2019 Jan 4; 14(1):e0208141.
90. Fisk RJ, Kumar D, Murphy DR, Arya M. Complementing EMR-based Interventions to Improve Hepatitis C Screening. Journal of translational internal medicine. 2018 Dec 1; 6(4):198-199.
91. Frost MC, Matson TE, Tsui JI, Williams EC. Influence of comorbid drug use disorder on receipt of evidence-based treatment for alcohol use disorder among VA patients with alcohol use disorder and Hepatitis C and/or HIV. Drug and Alcohol Dependence. 2019 Jan 1; 194:288-295.
92. Lynch SM, Wilson SM, DeRycke EC, Driscoll MA, Becker WC, Goulet JL, Kerns RD, Mattocks KM, Brandt CA, Bathulapalli H, Skanderson M, Haskell SG, Bastian LA. Impact of Cigarette Smoking Status on Pain Intensity Among Veterans With and Without Hepatitis C. Pain medicine (Malden, Mass.). 2018 Sep 1; 19(suppl_1):S5-S11.
93. Chhatwal J, Samur S, Bethea ED, Ayer T, Kanwal F, Hur C, Roberts MS, Terrault N, Chung RT. Transplanting hepatitis C virus-positive livers into hepatitis C virus-negative patients with preemptive antiviral treatment: A modeling study. Hepatology (Baltimore, Md.). 2018 Jun 1; 67(6):2085-2095.
94. Barnett PG, Joyce VR, Lo J, Gidwani-Marszowski R, Goldhaber-Fiebert JD, Desai M, Asch SM, Holodniy M, Owens DK. Effect of Interferon-Free Regimens on Disparities in Hepatitis C Treatment of US Veterans. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 2018 Aug 1; 21(8):921-930.
95. Yakovchenko V, Gifford AL, Matthews KL, Greenstone CL, Tsai J, McInnes DK. Improving VHA's Approach to Community Care: Lessons Learned From an Imperfect Hepatitis C Choice Program. Medical care. 2018 Mar 1; 56(3):274-276.
96. Rogal SS. Implementation Strategies and the Uptake of Hepatitis C Treatment in VA. QUERI Implementation Network [Cyberseminar]. VA HSR&D. 2018 Feb 1.
97. Chhatwal J, Chen Q, Ayer T, Bethea ED, Kanwal F, Kowdley KV, Wang X, Roberts MS, Gordon SC. Hepatitis C virus re-treatment in the era of direct-acting antivirals: projections in the USA. Alimentary pharmacology & therapeutics. 2018 Apr 1; 47(7):1023-1031.
98. Giordano NM, Brinn AJ, Garcia-Tsao G, Martino S. Patient perspectives on adherence to the new hepatitis C antiviral medications: 'a new lease on life. The qualitative report : an online journal dedicated to qualitative research since 1990. 2018 Jan 20; 23(1):184-203.
99. Konerman MA, Lu D, Zhang Y, Thomson M, Zhu J, Verma A, Liu B, Talaat N, Balis U, Higgins PDR, Lok ASF, Waljee AK. Assessing risk of fibrosis progression and liver-related clinical outcomes among patients with both early stage and advanced chronic hepatitis C. PLoS ONE. 2017 Nov 6; 12(11):e0187344.
100. Byrne DD, Tate JP, Forde KA, Lim JK, Goetz MB, Rimland D, Rodriguez-Barradas MC, Butt AA, Gibert CL, Brown ST, Bedimo R, Freiberg MS, Justice AC, Kostman JR, Roy JA, Lo Re V. Risk of Acute Liver Injury After Statin Initiation by Human Immunodeficiency Virus and Chronic Hepatitis C Virus Infection Status. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2017 Oct 16; 65(9):1542-1550.
101. Lovejoy TI, Morasco BJ, Kumthekar A, Shull S, Chang M, Barton J. Eradication of hepatitis C among US veterans: examination of changes in pain severity and prescription opioid use following treatment. [Abstract]. Arthritis + Rheuma.. 2017 Sep 27; 69(10):2221.
102. Lin M, Kramer J, White D, Cao Y, Tavakoli-Tabasi S, Madu S, Smith D, Asch SM, El-Serag HB, Kanwal F. Barriers to hepatitis C treatment in the era of direct-acting anti-viral agents. Alimentary pharmacology & therapeutics. 2017 Nov 1; 46(10):992-1000.
103. Kanwal F, Pyne JM, Tavakoli-Tabasi S, Nicholson S, Dieckgraefe B, Storay E, Goetz MB, Kramer JR, Smith D, Sansgiry S, Tansel A, Gifford AL, Asch SM. A Randomized Trial of Off-Site Collaborative Care for Depression in Chronic Hepatitis C Virus. Health services research. 2018 Aug 1; 53(4):2547-2566.
104. Kramer JR, El-Serag HB, Taylor TJ, White DL, Asch SM, Frayne SM, Cao Y, Smith DL, Kanwal F. Hepatitis C virus-related complications are increasing in women veterans: A national cohort study. Journal of Viral Hepatitis. 2017 Nov 1; 24(11):955-965.
105. Rogal SS, McCarthy R, Reid A, Rodriguez KL, Calgaro L, Patel K, Daley M, Jonassaint NL, Zickmund SL. Primary Care and Hepatology Provider-Perceived Barriers to and Facilitators of Hepatitis C Treatment Candidacy and Adherence. Digestive diseases and sciences. 2017 Aug 1; 62(8):1933-1943.
106. Lo Re V, Zeldow B, Kallan MJ, Tate JP, Carbonari DM, Hennessy S, Kostman JR, Lim JK, Goetz MB, Gross R, Justice AC, Roy JA. Risk of liver decompensation with cumulative use of mitochondrial toxic nucleoside analogues in HIV/hepatitis C virus coinfection. Pharmacoepidemiology and drug safety. 2017 Oct 1; 26(10):1172-1181.
107. Noska AJ, Belperio PS, Loomis TP, O'Toole TP, Backus LI. Prevalence of Human Immunodeficiency Virus, Hepatitis C Virus, and Hepatitis B Virus Among Homeless and Nonhomeless United States Veterans. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2017 Jul 15; 65(2):252-258.
108. Tsai J, Yakovchenko V, Jones N, Skolnik A, Noska A, Gifford AL, McInnes DK. "Where's My Choice?" An Examination of Veteran and Provider Experiences With Hepatitis C Treatment Through the Veteran Affairs Choice Program. Medical care. 2017 Jul 1; 55 Suppl 7 Suppl 1:S13-S19.
109. Samur S, Kues B, Ayer T, Roberts MS, Kanwal F, Hur C, Donnell DMS, Chung RT, Chhatwal J. Cost Effectiveness of Pre- vs Post-Liver Transplant Hepatitis C Treatment With Direct-Acting Antivirals. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2018 Jan 1; 16(1):115-122.e10.
110. Rogal SS, Yakovchenko V, Waltz TJ, Powell BJ, Kirchner JE, Proctor EK, Gonzalez R, Park A, Ross D, Morgan TR, Chartier M, Chinman MJ. The association between implementation strategy use and the uptake of hepatitis C treatment in a national sample. Implementation science : IS. 2017 May 11; 12(1):60.
111. Kanwal F, Bacon BR, Beste LA, Brill JV, Gifford AL, Gordon SC, Horberg MA, Manthey JG, Reau N, Rustgi VK, Younossi ZM. Hepatitis C Virus Infection Care Pathway-A Report From the American Gastroenterological Association Institute HCV Care Pathway Work Group. Gastroenterology. 2017 May 1; 152(6):1588-1598.
112. Balakrishnan M, Glover MT, Kanwal F. Hepatitis C and Risk of Nonhepatic Malignancies. Clinics in liver disease. 2017 Aug 1; 21(3):543-554.
113. Chhatwal J, Samur S, Kues B, Ayer T, Roberts MS, Kanwal F, Hur C, Donnell DM, Chung RT. Optimal timing of hepatitis C treatment for patients on the liver transplant waiting list. Hepatology (Baltimore, Md.). 2017 Mar 1; 65(3):777-788.
114. Noska AJ, Belperio PS, Loomis TP, O'Toole TP, Backus LI. Engagement in the Hepatitis C Care Cascade Among Homeless Veterans, 2015. Public health reports (Washington, D.C. : 1974). 2017 Mar 1; 132(2):136-139.
115. Cucciare MA, Jamison AL, Combs AS, Joshi G, Cheung RC, Rongey C, Huggins J, Humphreys K. Adapting a computer-delivered brief alcohol intervention for veterans with Hepatitis C. Informatics for health & social care. 2017 Dec 1; 42(4):378-392.
116. Hernaez R, El-Serag H. Ongoing alcohol consumptions counteracts the benefits of sustained virological response in patients with well compensated hepatitis C cirrhosis: an observational study. Annals of hepatology. 2017 Jan 1; 16(1):16-20.
117. Suda KJ, Halbur DJ, Hunkler RJ, Matusiak LM, Schumock GT. Spending on Hepatitis C Antivirals in the United States, 2009-2015. Pharmacotherapy. 2017 Jan 1; 37(1):65-70.
118. Beste LA, Glorioso TJ, Ho PM, Au DH, Kirsh SR, Todd-Stenberg J, Chang MF, Dominitz JA, Barón AE, Ross D. Telemedicine Specialty Support Promotes Hepatitis C Treatment by Primary Care Providers in the Department of Veterans Affairs. The American journal of medicine. 2017 Apr 1; 130(4):432-438.e3.
119. Kabiri M, Chhatwal J, Donohue JM, Roberts MS, James AE, Dunn MA, Gellad WF. Long-term disease and economic outcomes of prior authorization criteria for Hepatitis C treatment in Pennsylvania Medicaid. Healthcare (Amsterdam, Netherlands). 2017 Sep 1; 5(3):105-111.
120. Morasco BJ, Greaves DW, Lovejoy TI, Turk DC, Dobscha SK, Hauser P. Development and Preliminary Evaluation of an Integrated Cognitive-Behavior Treatment for Chronic Pain and Substance Use Disorder in Patients with the Hepatitis C Virus. Pain medicine (Malden, Mass.). 2016 Dec 1; 17(12):2280-2290.
121. Tsui JI, Williams EC, Green PK, Berry K, Su F, Ioannou GN. Alcohol use and hepatitis C virus treatment outcomes among patients receiving direct antiviral agents. Drug and Alcohol Dependence. 2016 Dec 1; 169:101-109.
122. Bossi KE. HSR&D e-Pub Briefs-1: Summaries of select journal articles published by HSR&D investigators on Hepatitis C, Opioids, Surgery, Bipolar Disorder, and Obesity. 2016 Nov 1; 9(1).
123. Chhatwal J, Wang X, Ayer T, Kabiri M, Chung RT, Hur C, Donohue JM, Roberts MS, Kanwal F. Hepatitis C Disease Burden in the United States in the era of oral direct-acting antivirals. Hepatology (Baltimore, Md.). 2016 Nov 1; 64(5):1442-1450.
124. White DA, Anderson ES, Pfeil SK, Deering LJ, Todorovic T, Trivedi TK. Hepatitis C Virus Screening and Emergency Department Length of Stay. PLoS ONE. 2016 Oct 19; 11(10):e0164831.
125. Justice AC, Esserman D, Sarkar S, Levin FL, Skanderson M, Lim JK. Reply to: "Hepatitis C testing in U.S. veterans born 1945-1965: An update". [Letter to the Editor]. Journal of Hepatology. 2017 Jan 1; 66(1):239.
126. Liu S, Barnett PG, Holodniy M, Lo J, Joyce VR, Gidwani RA, Asch SM, Owens DK, Goldhaber-Fiebert JD. Cost-Effectiveness of Treatments for Genotype 1 Hepatitis C Virus Infection in Non-VA and VA Populations. MDM policy & practice. 2016 Oct 3; 1(1):https://doi.org/10.1177/2381468316671946.
127. Tsai J. "Where's my choice?" Experiences of veterans accessing Hepatitis C treatment in the VA and the Choice program. Poster session presented at: VA Rural Health State of the Science Conference; 2016 Sep 12; Washington, DC.
128. Yakovchenko V, McInnes DK. Experiences of Veterans Accessing Hepatitis C Treatment in the VA and the Choice Program. Poster session presented at: VA Rural Health State of the Science Conference; 2016 Sep 12; Washington, DC.
129. Yakovchenko V. Engaging CBOC PACTs in Increasing Hepatitis C Testing. Paper presented at: VA New England Healthcare System Improvement and Innovation Summit; 2016 Sep 7; Marlborough, MA.
130. El-Serag HB, Kramer J, Duan Z, Kanwal F. Epidemiology and outcomes of hepatitis C infection in elderly US Veterans. Journal of Viral Hepatitis. 2016 Sep 1; 23(9):687-96.
131. Tsai J. Delayed and confused: Experiences of veterans accessing Hepatitis C treatment through the Choice First program: Briefing before the Oral presentation for Examining the New Landscape of Care in the Community; 2016 Aug 8; Arlington, VA.
132. Yakovchenko V, McInnes DK. Experiences of Veterans and Providers Accessing Hepatitis C Treatment Through the Choice First Program. Paper presented at: VA HSR&D Field-Based Examining the New Landscape of Care in the Community for Veterans Meeting; 2016 Aug 8; Washington, DC.
133. Chereji E, Kern S, Fuller B, Morasco BJ, Phelps A, Hauser P. Co-occurring Depression, Chronic Pain and Substance Use Disorders in People with Hepatitis C. Open medicine journal. 2016 Jul 29; 3(Suppl 1: M5):79-103.
134. El-Serag HB, Kanwal F, Richardson P, Kramer J. Risk of hepatocellular carcinoma after sustained virological response in Veterans with hepatitis C virus infection. Hepatology (Baltimore, Md.). 2016 Jul 1; 64(1):130-7.
135. Kanwal F, Pyne JM, Tavakoli-Tabasi S, Nicholson S, Dieckgraefe B, Storay E, Bidwell Goetz M, Smith DL, Sansgiry S, Gifford A, Asch SM. Collaborative Care for Depression in Chronic Hepatitis C Clinics. Psychiatric services (Washington, D.C.). 2016 Oct 1; 67(10):1076-1082.
136. Chidi AP, Bryce CL, Donohue JM, Fine MJ, Landsittel DP, Myaskovsky L, Rogal SS, Switzer GE, Tsung A, Smith KJ. Economic and Public Health Impacts of Policies Restricting Access to Hepatitis C Treatment for Medicaid Patients. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 2016 Jun 1; 19(4):326-34.
137. Fraenkel L, Lim J, Garcia-Tsao G, Reyna V, Monto A, Bridges JF. Variation in Treatment Priorities for Chronic Hepatitis C: A Latent Class Analysis. The patient. 2016 Jun 1; 9(3):241-9.
138. Yakovchenko V, Gifford AL, Miller DR. Using Electronic Clinical Reminders for Hepatitis C Testing in a Veteran Birth-Cohort. June 2016. Poster session presented at: AcademyHealth Annual Research Meeting; 2016 Jun 1; Boston, MA.
139. Lin M, Kramer JR, White DL, Tavakoli-Tabasi S, El-Serag HB, Kanwal F. Barriers to Hepatitis C Treatment for the Veteran Population in the DAA Era. Poster session presented at: Digestive Disease Week Annual Conference; 2016 May 22; San Diego, CA.
140. Kanwal F, Kramer JR, El-Serag HB, Frayne S, Clark J, Cao Y, Taylor T, Smith D, White D, Asch SM. Race and Gender Differences in the Use of Direct Acting Antiviral Agents for Hepatitis C Virus. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2016 Aug 1; 63(3):291-9.
141. Sarkar S, Esserman DA, Skanderson M, Levin FL, Justice AC, Lim JK. Disparities in hepatitis C testing in U.S. veterans born 1945-1965. Journal of Hepatology. 2016 Aug 1; 65(2):259-65.
142. Morasco BJ, Greaves DW. Integrated cognitive-behavior therapy for chronic pain and substance use disorder in patients with hepatitis C: A treatment manual. 2016 Apr 25.
143. Gifford AL. Engaging CBOCs in Hepatitis C Testing. [Cyberseminar]. VA Hepatitis C Innovation Team. 2016 Apr 4.
144. Fraenkel L, Lim J, Garcia-Tsao G, Reyna V, Monto A. Examining Hepatitis C Virus Treatment Preference Heterogeneity Using Segmentation Analysis: Treat Now or Defer? Journal of clinical gastroenterology. 2016 Mar 1; 50(3):252-7.
145. Rogal SS, Arnold RM, Chapko M, Hanusa BV, Youk A, Switzer GE, Sevick MA, Bayliss NK, Zook CL, Chidi A, Obrosky DS, Zickmund SL. The Patient-Provider Relationship Is Associated with Hepatitis C Treatment Eligibility: A Prospective Mixed-Methods Cohort Study. PLoS ONE. 2016 Feb 22; 11(2):e0148596.
146. Chidi AP, Rogal S, Bryce CL, Fine MJ, Good CB, Myaskovsky L, Rustgi VK, Tsung A, Smith KJ. Cost-effectiveness of new antiviral regimens for treatment-naïve U.S. veterans with hepatitis C. Hepatology (Baltimore, Md.). 2016 Feb 1; 63(2):428-36.
147. White DL, Richardson P, Tayoub N, Davila JA, Kanwal F, El-Serag HB. The Updated Model: An Adjusted Serum Alpha-Fetoprotein-Based Algorithm for Hepatocellular Carcinoma Detection With Hepatitis C Virus-Related Cirrhosis. Gastroenterology. 2015 Dec 1; 149(7):1986-7.
148. Kramer JR, Richardson P, Liffman D, El-Serag HB, Rein DB. Costs per Diagnosed Liver Disease Stage Among Individuals with Chronic Hepatitis C Virus in the Veterans Health Administration. Paper presented at: American Association for the Study of Liver Diseases Annual Meeting; 2015 Nov 16; San Francisco, CA.
149. Krans EE, Zickmund SL, Rustgi VK, Park SY, Dunn SL, Schwarz EB. Screening and evaluation of hepatitis C virus infection in pregnant women on opioid maintenance therapy: A retrospective cohort study. Substance Abuse. 2015 Nov 16; 37(1):88-95.
150. Kanwal F, Kramer JR, Cao Y, Taylor T, Smith DL, Asch S, El-Serag HB. Demographic Predictors of Direct Acting Antiviral Receipt in Individuals with Hepatitis C Virus Infection. Presented at: American Association for the Study of Liver Diseases Annual Meeting; 2015 Nov 15; San Francisco, CA.
151. Chhatwal J, Wang X, Kanwal F, Kabiri M, Ayer T, Donohue JM, Roberts MS. Hepatitis C Disease Burden in the United States in 2015 and Beyond. Poster session presented at: American Association for the Study of Liver Diseases Annual Meeting; 2015 Nov 13; San Francisco, CA.
152. Chhatwal J, Wang X, Roberts MS, Kabiri M, Ayer T, Donohue J, Kanwal F. The Cost of Making Hepatitis C a Rare Disease in the United States. Presented at: American Association for the Study of Liver Diseases Annual Meeting; 2015 Nov 13; San Francisco, CA.
153. Kanwal F, Kramer JR, Cao Y, Taylor T, Smith DL, Asch S, El-Serag HB. Demographic Predictors of Direct Acting Antiviral Receipt in Individuals with Hepatitis C Virus Infection. Poster session presented at: American Association for the Study of Liver Diseases Annual Meeting; 2015 Nov 13; San Francisco, CA.
154. Adams MH, Lovejoy TI, Turk DC, Dobscha SK, Hauser P, Morasco BJ. Pain-related anxiety mediates the relationship between depressive symptoms and pain interference in veterans with hepatitis C. General hospital psychiatry. 2015 Nov 1; 37(6):533-7.
155. Ho SB, Bräu N, Cheung R, Liu L, Sanchez C, Sklar M, Phelps TE, Marcus SG, Wasil MM, Tisi A, Huynh L, Robinson SK, Gifford AL, Asch SM, Groessl EJ. Integrated Care Increases Treatment and Improves Outcomes of Patients With Chronic Hepatitis C Virus Infection and Psychiatric Illness or Substance Abuse. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2015 Nov 1; 13(11):2005-14.e1-3.
156. LaFleur J, Hoop R, Korner E, DuVall S, Morgan T, Pandya P, Han J, Knippenberg K, Nelson RE. Predictors of Early Discontinuation of Pegylated Interferon for Reasons Other Than Lack of Efficacy in United States Veterans With Chronic Hepatitis C. Gastroenterology Nursing : The Official Journal of The Society of Gastroenterology Nurses and Associates. 2015 Nov 1; 38(6):417-28.
157. Pyne JM. Expanding the Scope of Integrated Behavioral Health Care for Patients With Hepatitis C Virus. [Letter to the Editor]. Clinical Gastroenterology and Hepatology. 2015 Nov 1; 13(11):2015-6.
158. McInnes D, Bolton RE, Solomon J, Steinhauser KE. Complexity of patient-caregiver relationships in veterans undergoing hepatitis C treatment. Poster session presented at: American Public Health Association Annual Meeting and Exposition; 2015 Oct 31; Chicago, IL.
159. Chhatwal J, Chen Q, Kanwal F. Why We Should Be Willing to Pay for Hepatitis C Treatment. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2015 Oct 1; 13(10):1711-3.
160. Zuchowski JL, Hamilton AB, Pyne JM, Clark JA, Naik AD, Smith DL, Kanwal F. Qualitative analysis of patient-centered decision attributes associated with initiating hepatitis C treatment. BMC gastroenterology. 2015 Oct 1; 15:124.
161. Kanwal F. Issue Highlights: Evidence Against Routine Testing of Patients With Functional Gastrointestinal Disorders for Celiac Disease: A Population-based Study, Efficacy of a Chinese Herbal Medicine in Providing Adequate Relief of Constipation-predominant Irritable Bowel Syndrome: A Randomized Controlled Trial, and Efficacy of Sofosbuvir and Daclatasvir in Patients With Fibrosing Cholestatic Hepatitis C After Liver Transplantation. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2015 Sep 20; 13(11):1993–2001.e2.
162. Kanwal F. Issue Highlights: Sofosbuvir and Daclatasvir Improve Outcomes of Patients With Fibrosing Cholestatic Hepatitis C. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2015 Sep 20; 13(11):1859.
163. Good CB. Hepatitis C: update on reimbursement, treatments, and screening policies. Presented at: Vancouver Group of Competent Prescription Authorities International Meeting; 2015 Sep 8; Stockholm, Sweden.
164. Clark JA, Gifford AL. Resolute efforts to cure hepatitis C: Understanding patients' reasons for completing antiviral treatment. Health (London, England : 1997). 2015 Sep 1; 19(5):473-89.
165. Lo Re V, Kallan MJ, Tate JP, Lim JK, Goetz MB, Klein MB, Rimland D, Rodriguez-Barradas MC, Butt AA, Gibert CL, Brown ST, Park LS, Dubrow R, Reddy KR, Kostman JR, Justice AC, Localio AR. Predicting Risk of End-Stage Liver Disease in Antiretroviral-Treated Human Immunodeficiency Virus/Hepatitis C Virus-Coinfected Patients. Open forum infectious diseases. 2015 Sep 1; 2(3):ofv109.
166. Butt AA, Yan P, Bonilla H, Abou-Samra AB, Shaikh OS, Simon TG, Chung RT, Rogal SS, ERCHIVES (Electronically Retrieved Cohort of HCV Infected Veterans) Study Team. Effect of addition of statins to antiviral therapy in hepatitis C virus-infected persons: Results from ERCHIVES. Hepatology (Baltimore, Md.). 2015 Aug 1; 62(2):365-74.
167. Khalaf N, White D, Kanwal F, Ramsey D, Mittal S, Tavakoli-Tabasi S, Kuzniarek J, El-Serag HB. Coffee and Caffeine Are Associated With Decreased Risk of Advanced Hepatic Fibrosis Among Patients With Hepatitis C. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2015 Aug 1; 13(8):1521-31.e3.
168. Good CB. Hepatitis C: many challenges. Presented at: Canadian Drug Expert Committee and Drug Policy Advisory Committee Conference; 2015 Jul 16; Halifax, Canada.
169. Gundlapalli AV, Nelson RE, Haroldsen C, Carter ME, LaFleur J. Correlates of Initiation of Treatment for Chronic Hepatitis C Infection in United States Veterans, 2004-2009. PLoS ONE. 2015 Jul 13; 10(7):e0132056.
170. Taylor T, Avoundjian T, Wu J, Asch SM, Midboe AM. Evaluating 6 Hepatitis C Case Finding Algorithms using Electronic Administrative Data in the Absence of a Gold-Standard. Paper presented at: VA HSR&D / QUERI National Meeting; 2015 Jul 9; Philadelphia, PA.
171. Kanwal F, Pyne JM, Tavakoli-Tabasi S, Dieckgraefe B, Goetz MB, Smith DL, Kramer JR, Sansgiry S, Gifford AL, Asch SM. Collaborative Care for Depression in Chronic Hepatitis C Clinics. Paper presented at: VA HSR&D / QUERI National Meeting; 2015 Jul 8; Philadelphia, PA.
172. Cucciare MA, Cheung RC, Rongey C. Treating substance use disorders in patients with hepatitis C. [Editorial]. Addiction. 2015 Jul 1; 110(7):1057-9.
173. Kanwal F, White DL, Jiao L, Tavakoli-Tabasi S, Sansgiry S, Ramsey DJ, Kuzniarek J, Spiegelman A, El-Serag HB. Genetic Variants in Interleukin-28B Are Associated with Diabetes and Diabetes-Related Complications in Patients with Chronic Hepatitis C Virus Infection. Digestive diseases and sciences. 2015 Jul 1; 60(7):2030-7.
174. May MT, Justice AC, Birnie K, Ingle SM, Smit C, Smith C, Neau D, Guiguet M, Schwarze-Zander C, Moreno S, Guest JL, Monforte Ad, Tural C, Gill MJ, Bregenzer A, Kirk O, Saag M, Sterling TR, Crane HM, Sterne JA. Injection Drug Use and Hepatitis C as Risk Factors for Mortality in HIV-Infected Individuals: The Antiretroviral Therapy Cohort Collaboration. Journal of acquired immune deficiency syndromes (1999). 2015 Jul 1; 69(3):348-54.
175. Konerman MA, Zhang Y, Zhu J, Higgins PD, Lok AS, Waljee AK. Improvement of predictive models of risk of disease progression in chronic hepatitis C by incorporating longitudinal data. Hepatology (Baltimore, Md.). 2015 Jun 1; 61(6):1832-41.
176. Suda KJ, Vermeulen LC, Hunkler RJ, Matusiak LM, Schumock GT. Spending On Hepatitis C Antivirals in the United States, 2008-2014. Poster session presented at: International Society for Pharmacoeconomics and Outcomes Research Annual Meeting; 2015 May 19; Philadelphia, PA.
177. El-Serag HB, Duan Z, Kanwal F. Hepatitis C Infection in Elderly U.S. Veterans: Treatment Related Outcomes. Poster session presented at: Digestive Disease Week Annual Conference; 2015 May 16; Washington, DC.
178. El-Serag HB, Duan Z, Kramer JR, Kanwal F. Treatment and Outcomes of Chronic Hepatitis C (CHC) in the Elderly. Poster session presented at: Digestive Disease Week Annual Conference; 2015 May 16; Washington, DC.
179. Nguyen T, El-Serag HB, White D, Ramsey D, Kalin A, Kuzniarek J, Kanwal F. Angiotensin Converting Enzyme Inhibitors (ACEi) Are Not Associated with Severity of Fibrosis in Patients with Hepatitis C Virus (HCV). Paper presented at: Digestive Disease Week Annual Conference; 2015 May 16; Washington, DC.
180. Gidwani R, Barnett PG, Goldhaber-Fiebert JD, Asch SM, Lo J, Dally SK, Owens DK. Uptake and utilization of directly acting antiviral medications for hepatitis C infection in U.S. veterans. Journal of Viral Hepatitis. 2015 May 1; 22(5):489-95.
181. Morasco BJ, Greaves DW, Lovejoy TI, Turk DC, Dobscha SK, Hauser P. Development and preliminary evaluation of an integrated cognitive-behavior treatment for patients with the hepatitis C virus who have comorbid chronic pain and substance use disorder. [Abstract]. The journal of pain : official journal of the American Pain Society. 2015 Apr 1; 16(1):S98.
182. Chhatwal J, Kanwal F, Roberts MS, Dunn MA. Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States. Annals of internal medicine. 2015 Mar 17; 162(6):397-406.
183. Butt AA, Yan P, Lo Re V, Rimland D, Goetz MB, Leaf D, Freiberg MS, Klein MB, Justice AC, Sherman KE, ERCHIVES (Electronically Retrieved Cohort of HCV Infected Veterans) Study Team. Liver fibrosis progression in hepatitis C virus infection after seroconversion. JAMA internal medicine. 2015 Feb 1; 175(2):178-85.
184. Kruse RL, Kramer JR, Tyson GL, Duan Z, Chen L, El-Serag HB, Kanwal F. Clinical outcomes of hepatitis B virus coinfection in a United States cohort of hepatitis C virus-infected patients. Hepatology (Baltimore, Md.). 2014 Dec 1; 60(6):1871-8.
185. Chidi AP, Rogal SS, Fine MJ, Good CB, Myaskovsky L. Cost-effectiveness of novel hepatitis C drug regimens among treatment-experienced US Veterans. Presented at: American Association for the Study of Liver Diseases Annual Meeting; 2014 Nov 10; Boston, MA.
186. Rogal SS, Youk AO, Chapko MK, Hanusa BH, Arnold RM, Switzer GE, Sevick MA, Bayliss NK, Zook CL, Obrosky DS, Zickmund SL. Factors associated with hepatitis C treatment eligibility. Poster session presented at: American Association for the Study of Liver Diseases Annual Meeting; 2014 Nov 10; Boston, MA.
187. Zickmund SL, Chapko ML, Hanusa BV, Youk A, Switzer GE, Sevick MA, Bayliss N, Zook C, Obrosky DS, Arnold RA. Barriers to initiating treatment for hepatitis C: results of a Veteran population. Presented at: American Association for the Study of Liver Diseases Annual Meeting; 2014 Nov 10; Boston, MA.
188. Zickmund SL, Chapko ML, Hanusa BV, Youk A, Switzer GE, Sevick MA, Bayliss N, Zook C, Obrosky DS, Arnold RA. Predictors of attendance at GI to discuss treatment for hepatitis C. Presented at: American Association for the Study of Liver Diseases Annual Meeting; 2014 Nov 10; Boston, MA.
189. Demian N, Mitchell M, Warburton A, Arnold R, Switzer GE, Sevick MA, Bayliss NK, Chapko MK, Zickmund SL. Stigmatization and hepatitis C in a Veteran population: comparisons of substance users and non-substance users. Presented at: American Association for the Study of Liver Diseases Annual Meeting; 2014 Nov 9; Boston, MA.
190. Warburton A, Mitchell MA, Demian N, Arnold RM, Switzer GE, Sevick MA, Bayliss NK, Chapko MK, Zickmund SL. Veterans with hepatitis C report negative experiences communicating with their providers. Presented at: American Association for the Study of Liver Diseases Annual Meeting; 2014 Nov 9; Boston, MA.
191. Chidi A, Rogal SS, Bryce CL, Fine MJ, Good CB, Myaskovsky L, Rustgi V, Tsung A, Smith KJ. Cost-effectiveness of novel regimens for treatment-naïve US Veterans with hepatitis C. Poster session presented at: Society for Medical Decision Making Annual Meeting; 2014 Oct 22; Miami, FL.
192. White DL, Liu Y, Garcia J, El-Serag HB, Jiao L, Tsavachidis S, Franco LM, Lee JS, Tavakoli-Tabasi S, Moore D, Goldman R, Kuzniarek J, Ramsey DJ, Kanwal F, Marcelli M. Sex hormone pathway gene polymorphisms are associated with risk of advanced hepatitis C-related liver disease in males. International journal of molecular epidemiology and genetics. 2014 Oct 22; 5(3):164-76.
193. Chidi A, Rogal SS, Bryce CL, Fine MJ, Good CB, Myaskovsky L, Rustgi V, Tsung A, Smith KJ. Cost-effectiveness of novel regimens for treatment-experienced US Veterans with hepatitis C. [Abstract]. Hepatology. 2014 Oct 1; 60(S1):234A.
194. Morasco BJ, Lovejoy TI, Turk DC, Crain A, Hauser P, Dobscha SK. Biopsychosocial factors associated with pain in veterans with the hepatitis C virus. Journal of behavioral medicine. 2014 Oct 1; 37(5):902-11.
195. Pocha C, Knott A, Rector TS, Dieperink E. Are selective serotonin reuptake inhibitors associated with hepatocellular carcinoma in patients with hepatitis C? The Journal of clinical psychiatry. 2014 Oct 1; 75(10):e1122-6.
196. Rogal SS, Arnold RM, Chapko MK, Hanusa BH, Youk AO, Switzer GE, Sevick MA, Bayliss NK, Zook CL, Chidi A, Obrosky DS, Zickmund SL. Factors associated with hepatitis C treatment eligibility. [Abstract]. Hepatology. 2014 Oct 1; 60(S1):901A.
197. Taylor-Young P, Miller D, Ganzini LK, Golden S, Hansen L. Feasibility and Acceptability of Group Acupuncture in Veterans with Hepatitis C: A Pilot Study. Medical acupuncture. 2014 Aug 22; 26(4):208-214.
198. Kanwal F, El-Serag HB. Hepatitis C virus treatment: the unyielding chasm between efficacy and effectiveness. Clinical Gastroenterology and Hepatology. 2014 Aug 1; 12(8):1381-3.
199. Morbitzer KA, Taber DJ, Pilch NA, Meadows HB, Fleming JN, Bratton CF, McGillicuddy JW, Baliga PK, Chavin KD. The impact of diabetes mellitus and glycemic control on clinical outcomes following liver transplant for hepatitis C. Clinical Transplantation. 2014 Aug 1; 28(8):862-8.
200. Zuchowski J, Hamilton AB, Pyne J, Clark J, Smith D, Kanwal F. Gender differences in treatment decision-making among Veterans with hepatitis C. Poster session presented at: VA HSR&D Enhancing Partnerships for Research and Care of Women Veterans Conference; 2014 Jul 31; Arlington, VA.
201. Nelson RE, Hoop R, Korner E, DuVall S, Hayden CL, Knippenberg K, Morgan T, Pandya P, Han J, LaFleur J. Predicting Discontinuation of Pegylated Interferon as a Result of Lack of Efficacy in United States Veterans With Chronic Hepatitis C on Dual Therapy. The Annals of pharmacotherapy. 2014 Jul 1; 48(7):826-836.
202. Wong RJ, Kanwal F, Younossi ZM, Ahmed A. Hepatitis C virus infection and coronary artery disease risk: a systematic review of the literature. Digestive diseases and sciences. 2014 Jul 1; 59(7):1586-93.
203. Sansgiry S, Pyne J, Smith D, Brown AC, Hodges D, Stanley R, Kanwal F. Health-related quality of life in chronic hepatitis C patients with depression. Poster session presented at: International Society for Pharmacoeconomics and Outcomes Research Annual Meeting; 2014 Jun 3; Montreal, Canada.
204. Kruse R, Kramer JR, Duan Z, Chen L, El-Serag HB, Kanwal F. Impact of Active Hepatitis B Virus DNA Replication on Clinical Outcomes in Patients with Hepatitis C and B Co-infection. Paper presented at: Digestive Disease Week Annual Meeting; 2014 May 5; Chicago, IL.
205. White DL, Liu Y, Tsavachidis S, Tavakoli-Tabasi S, Kuzniarek J, Jiao L, Ramsey DJ, Kanwal F, Francis J, El-Serag HB. Sex Hormone Pathway Gene Polymorphisms Are Associated with Risk of Advanced Hepatitis C-Related Liver Disease in Males. Poster session presented at: Digestive Disease Week Annual Meeting; 2014 May 4; Chicago, IL.
206. El-Serag HB, Kanwal F, Davila JA, Kramer J, Richardson P. A new laboratory-based algorithm to predict development of hepatocellular carcinoma in patients with hepatitis C and cirrhosis. Gastroenterology. 2014 May 1; 146(5):1249-55.e1.
207. Lim JK, Tate JP, Fultz SL, Goulet JL, Conigliaro J, Bryant KJ, Gordon AJ, Gibert C, Rimland D, Goetz MB, Klein MB, Fiellin DA, Justice AC, Lo Re V. Relationship between alcohol use categories and noninvasive markers of advanced hepatic fibrosis in HIV-infected, chronic hepatitis C virus-infected, and uninfected patients. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2014 May 1; 58(10):1449-58.
208. LaFleur J, Hoop R, Morgan T, DuVall SL, Pandya P, Korner E, Knippenberg K, Hayden C, Nelson RE. High rates of early treatment discontinuation in hepatitis C-infected US veterans. BMC research notes. 2014 Apr 24; 7:266.
209. Taylor-Young P. Feasibility and Acceptability of Group Acupuncture in Veterans with Hepatitis C: A Pilot Study. Poster session presented at: Western Institute of Nursing Annual Meeting; 2014 Apr 10; Seattle, WA.
210. Sussman NL, Remien CH, Kanwal F. The end of hepatitis C. [Editorial]. Clinical Gastroenterology and Hepatology. 2014 Apr 1; 12(4):533-6.
211. Lo Re V, Kallan MJ, Tate JP, Localio AR, Lim JK, Goetz MB, Klein MB, Rimland D, Rodriguez-Barradas MC, Butt AA, Gibert CL, Brown ST, Park L, Dubrow R, Reddy KR, Kostman JR, Strom BL, Justice AC. Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: a cohort study. Annals of internal medicine. 2014 Mar 18; 160(6):369-79.
212. Anderson JP, Tchetgen Tchetgen EJ, Lo Re V, Tate JP, Williams PL, Seage GR, Horsburgh CR, Lim JK, Goetz MB, Rimland D, Rodriguez-Barradas MC, Butt AA, Klein MB, Justice AC. Antiretroviral therapy reduces the rate of hepatic decompensation among HIV- and hepatitis C virus-coinfected veterans. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2014 Mar 1; 58(5):719-27.
213. Younossi ZM, Kanwal F, Saab S, Brown KA, El-Serag HB, Kim WR, Ahmed A, Kugelmas M, Gordon SC. The impact of hepatitis C burden: an evidence-based approach. Alimentary pharmacology & therapeutics. 2014 Mar 1; 39(5):518-31.
214. Kanwal F, Hoang T, Chrusciel T, Kramer JR, El-Serag HB, Durfee J, Dominitz JA, Yano EM, Asch SM. Association between facility characteristics and the process of care delivered to patients with hepatitis C virus infection. Digestive diseases and sciences. 2014 Feb 1; 59(2):273-81.
215. Southern WN, Drainoni ML, Smith BD, Koppelman E, McKee MD, Christiansen CL, Gifford AL, Weinbaum CM, Litwin AH. Physician nonadherence with a hepatitis C screening program. Quality management in health care. 2014 Jan 1; 23(1):1-9.
216. Bachhuber MA, Cunningham CO. Changes in testing for human immunodeficiency virus, sexually transmitted infections, and hepatitis C virus in opioid treatment programs. JAMA. 2013 Dec 25; 310(24):2671-2.
217. Groessl EJ, Ho SB, Asch SM, Stepnowsky CJ, Laurent D, Gifford AL. The hepatitis C self-management program: sustainability of primary outcomes at 1 year. Health education & behavior : the official publication of the Society for Public Health Education. 2013 Dec 1; 40(6):730-40.
218. Moyer VA, U. S. Preventive Services Task Force. Screening for hepatitis C virus infection in adults: U.S. Preventive Services Task Force recommendation statement. Annals of internal medicine. 2013 Sep 3; 159(5):349-57.
219. French AL, Evans CT, Agniel DM, Cohen MH, Peters M, Landay AL, Desai SN. Microbial translocation and liver disease progression in women coinfected with HIV and hepatitis C virus. The Journal of Infectious Diseases. 2013 Aug 15; 208(4):679-89.
220. Tyson GL, Kramer JR, Duan Z, Davila JA, Richardson PA, El-Serag HB. Prevalence and predictors of hepatitis B virus coinfection in a United States cohort of hepatitis C virus-infected patients. Hepatology (Baltimore, Md.). 2013 Aug 1; 58(2):538-45.
221. Groessl EJ, Sklar M, Cheung RC, Bräu N, Ho SB. Increasing antiviral treatment through integrated hepatitis C care: a randomized multicenter trial. Contemporary clinical trials. 2013 Jul 1; 35(2):97-107.
222. Heslin KC, Guerrero EG, Mitchell MN, Afable MK, Dobalian A. Explaining differences in hepatitis C between U.S. veterans and nonveterans in treatment for substance abuse: results from a regression decomposition. Substance use & misuse. 2013 Jul 1; 48(10):854-62.
223. Tyson GL, Richardson PA, White DL, Kuzniarek J, Ramsey DJ, Tavakoli-Tabasi S, El-Serag HB. Dietary fructose intake and severity of liver disease in hepatitis C virus-infected patients. Journal of clinical gastroenterology. 2013 Jul 1; 47(6):545-52.
224. White DL, Tavakoli-Tabasi S, Kanwal F, Ramsey DJ, Hashmi A, Kuzniarek J, Patel P, Francis J, El-Serag HB. The association between serological and dietary vitamin D levels and hepatitis C-related liver disease risk differs in African American and white males. Alimentary pharmacology & therapeutics. 2013 Jul 1; 38(1):28-37.
225. Hanks D. Management eBrief-l: Assessment of Alternative Treatment Strategies for Chronic Genotype 1 Hepatitis C. 2013 Jun 4; 5(67).
226. Kramer JR, Kowalkowski M, Duan Z, El-Serag HB, Chiao E. Effect of Hepatitis C Viral Factors and Overall Immune Suppression on the Risk of Hepatocellular Carcinoma in Patients with HCV-HIV Coinfection. Paper presented at: Digestive Disease Week Annual Meeting; 2013 May 20; Orlando, FL.
227. Kanwal F. Liver related mortality in patients with hepatitis C virus infection. Paper presented at: Chronic Liver Disease Foundation Quarterly Panel Meeting; 2013 May 9; Washington, DC.
228. Hanks D. Emerging Evidence-2: Apr '13-HIV and Hepatitis C. 2013 Apr 30; 4(2).
229. Goldhaber-Fiebert JD, Barnett PG, Dally S, Asch SM, Liu S, Cipriano L, Owens DK, Miake-Lye IM, Beroes JM, Shekelle PG. Assessment of Alternative Treatment Strategies for Chronic Genotype 1 Hepatitis C. Washington (DC): Department of Veterans Affairs; 2013 Mar 1. 37 p. Report No.: VA ESP Project #05-226.
230. Kanwal F, Lok AS, El-Serag HB. CDC and USPSTF 2012 recommendations for screening for hepatitis C virus infection: overview and take-home messages. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2013 Mar 1; 11(3):200-3.
231. Kanwal F, Lok AS, El-Serag HB. CDC and USPSTF 2012 recommendations for screening for hepatitis C virus infection: overview and take-home messages. Gastroenterology. 2013 Mar 1; 144(3):478-81.
232. McInnes DK, Solomon JL, Shimada SL, Petrakis BA, Bokhour BG, Asch SM, Nazi KM, Houston TK, Gifford AL. Development and evaluation of an internet and personal health record training program for low-income patients with HIV or hepatitis C. Medical care. 2013 Mar 1; 51(3 Suppl 1):S62-6.
233. El-Serag HB. Treating Patients with Hepatitis C to Prevent Related Diseases HCC/Cholangiocarcinoma. Paper presented at: American Association for the Study of Liver Diseases - Single Topic Conference; 2013 Feb 14; Atlanta, GA.
234. Zickmund SL. Racial disparities in treatment for hepatitis C: a longitudinal mixed methods approach. Poster session presented at: National Institutes of Health Science of Eliminating Health Disparities Annual Summit; 2012 Dec 17; National Harbor, MD.
235. Calore BL, Cheung RC, Giori NJ. Prevalence of hepatitis C virus infection in the veteran population undergoing total joint arthroplasty. Journal of Arthroplasty. 2012 Dec 1; 27(10):1772-6.
236. Oser M, Cucciare M, McKellar J, Weingardt K. Correlates of hazardous drinking among Veterans with and without hepatitis C. Journal of behavioral medicine. 2012 Dec 1; 35(6):634-41.
237. Drainoni ML, Litwin AH, Smith BD, Koppelman EA, McKee MD, Christiansen CL, Gifford AL, Weinbaum CM, Southern WN. Effectiveness of a risk screener in identifying hepatitis C virus in a primary care setting. American journal of public health. 2012 Nov 1; 102(11):e115-21.
238. Kanwal F, Hoang T, Chrusciel T, Kramer JR, El-Serag HB, Dominitz JA, Asch SM. Process of care for hepatitis C infection is linked to treatment outcome and virologic response. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2012 Nov 1; 10(11):1270-1277.e3.
239. Lo Re V, Volk J, Newcomb CW, Yang YX, Freeman CP, Hennessy S, Kostman JR, Tebas P, Leonard MB, Localio AR. Risk of hip fracture associated with hepatitis C virus infection and hepatitis C/human immunodeficiency virus coinfection. Hepatology (Baltimore, Md.). 2012 Nov 1; 56(5):1688-98.
240. Lovejoy TI, Dobscha SK, Cavanagh R, Turk DC, Morasco BJ. Chronic pain treatment and health service utilization of veterans with hepatitis C virus infection. Pain medicine (Malden, Mass.). 2012 Nov 1; 13(11):1407-16.
241. Smith-Spangler CM, Asch SM. Commentary on Vickerman et?al. (2012): Reducing hepatitis C virus among injection drug users through harm reduction programs. Addiction. 2012 Nov 1; 107(11):1996-7.
242. White DL, Hashmi A, Ramsey DJ, Kuzniarek J, Tavakoli-Tabasi S, El-Serag HB. Finasteride and methadone use and risk of advanced hepatitis C related liver disease. Digestive diseases and sciences. 2012 Nov 1; 57(11):3004-10.
243. Kanwal F, Hoang T, Kramer J, Chrusciel T, El-Serag H, Dominitz JA, Asch SM. The performance of process measures in hepatitis C. The American journal of gastroenterology. 2012 Oct 1; 107(10):1512-21.
244. White DL, Tavakoli-Tabasi S, Kuzniarek J, Ramsey DJ, El-Serag HB. Racial differences in the association between adiposity measures and the risk of hepatitis C-related liver disease. Journal of clinical gastroenterology. 2012 Oct 1; 46(9):779-88.
245. Norton BL, Park L, McGrath LJ, Proeschold Bell RJ, Muir AJ, Naggie S. Health care utilization in HIV-infected patients: assessing the burden of hepatitis C virus coinfection. AIDS Patient Care and Stds. 2012 Sep 1; 26(9):541-5.
246. Zickmund SL, Campbell SA, Tirado CF, Zook CL, Weinrieb RM. Perceived barriers to hepatitis C therapy for patients receiving opioid agonist treatment. Journal of addiction medicine. 2012 Sep 1; 6(3):233-9.
247. Groessl EJ, Liu L, Ho SB, Kanwal F, Gifford AL, Asch SM. National patterns and predictors of liver biopsy use for management of hepatitis C. Journal of Hepatology. 2012 Aug 1; 57(2):252-9.
248. Fix GM, Bolton RE, Drainoni M, Koppelman E, Gifford AL, Clark JA. The impact of work on patients’ abilities to complete hepatitis C treatment. Paper presented at: VA HSR&D / QUERI National Meeting; 2012 Jul 18; National Harbor, MD.
249. Zickmund SL, Hanusa BH, Obrosky DS, Chapko MK, Bayliss NK, Switzer GE, Sevick MA, Zook CL, Mrkva A, Arnold RM. Racial disparities in the initiation of hepatitis C antiviral therapy. Poster session presented at: VA HSR&D / QUERI National Meeting; 2012 Jul 17; National Harbor, MD.
250. Chan K, Lai MN, Groessl E, Hanchate A, Wong JB, Clark JA, Asch SM, Gifford AL, Ho SB. Potential Costs Associated with New Direct-Acting Antivirals (DAAs) therapy for untreated Chronic Hepatitis C genotype 1 infection in the Veterans Health Administration. Poster session presented at: VA HSR&D / QUERI National Meeting; 2012 Jul 16; National Harbor, MD.
251. Litwin AH, Smith BD, Drainoni ML, McKee D, Gifford AL, Koppelman E, Christiansen CL, Weinbaum CM, Southern WN. Primary care-based interventions are associated with increases in hepatitis C virus testing for patients at risk. Digestive and Liver Disease : Official Journal of The Italian Society of Gastroenterology and The Italian Association For The Study of The Liver. 2012 Jun 1; 44(6):497-503.
252. Tyson G, Duan Z, Kramer JR, Davila J, Richardson PA, Kanwal F, El-Serag HB. Clinical outcomes of hepatitis B co-infection in a United States cohort with hepatitis C. Poster session presented at: Digestive Disease Week Annual Meeting; 2012 May 21; San Diego, CA.
253. White DL, Green LK, Tavakoli-Tabasi S, Kuzniarek J, Ramsey DJ, Sansgiry S, Francis J, El-Serag HB. Higher total serum testosterone level is associated with increased risk of biopsy-confirmed advanced hepatic fibrosis and inflammation but not advanced steatosis in male Veterans with chronic hepatitis C. Poster session presented at: Digestive Disease Week Annual Meeting; 2012 May 19; San Diego, CA.
254. Bilka NJ, Baker E, Hournieh A. A retrospective analysis of telaprevir therapy for chronic hepatitis C virus (HCV) infection Veterans Affairs Boston Healthcare System (VABHS): A pilot study. Poster session presented at: Eastern States Conference for Pharmacy Residents and Preceptors; 2012 May 3; Hershey, PA.
255. Lovejoy TI, Dobscha SK, Cavanagh R, Turk DC, Morasco BJ. Chronic pain treatment and medical utilization among patients with hepatitis C. [Abstract]. Annals of behavioral medicine : a publication of the Society of Behavioral Medicine. 2012 Apr 11; 13(11):1407-1416.
256. Clark BT, Garcia-Tsao G, Fraenkel L. Patterns and predictors of treatment initiation and completion in patients with chronic hepatitis C virus infection. Patient preference and adherence. 2012 Apr 4; 6:285-95.
257. Richardson P, Duan Z, Kramer J, Davila JA, Tyson GL, El-Serag HB. Determinants of serum alpha-fetoprotein levels in hepatitis C-infected patients. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2012 Apr 1; 10(4):428-33.
258. Saifu HN, Asch SM, Goetz MB, Smith JP, Graber CJ, Schaberg D, Sun BC. Evaluation of human immunodeficiency virus and hepatitis C telemedicine clinics. The American journal of managed care. 2012 Apr 1; 18(4):207-12.
259. White DL, Tavakoli-Tabasi S, Kuzniarek J, Pascua R, Ramsey DJ, El-Serag HB. Higher serum testosterone is associated with increased risk of advanced hepatitis C-related liver disease in males. Hepatology (Baltimore, Md.). 2012 Mar 1; 55(3):759-68.
260. Layden JE, Cotler SJ, Grim SA, Fischer MJ, Lucey MR, Clark NM. Impact of donor and recipient race on survival after hepatitis C-related liver transplantation. Transplantation. 2012 Feb 27; 93(4):444-9.
261. Liu S, Cipriano LE, Holodniy M, Owens DK, Goldhaber-Fiebert JD. New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis. Annals of internal medicine. 2012 Feb 21; 156(4):279-90.
262. Rongey CA, Asch SM. Access to care for vulnerable Veterans with hepatitis C: a hybrid conceptual framework and a case study to guide translation. Translational behavioral medicine. 2011 Dec 22; 1(4):1-8.
263. Chapman J, Oser M, Hockemeyer J, Weitlauf J, Jones S, Cheung R. Changes in depressive symptoms and impact on treatment course among hepatitis C patients undergoing interferon-a and ribavirin therapy: a prospective evaluation. The American journal of gastroenterology. 2011 Dec 1; 106(12):2123-32.
264. Cucciare MA, Weingardt KR. Commentary on Gibson et al. (2011): Brief alcohol interventions in the context of treatment for hepatitis C. Addiction. 2011 Dec 1; 106(12):2193-4.
265. Oser ML, Cucciare MA, McKellar JD, Weingardt KR. Correlates of hazardous drinking among Veterans with and without hepatitis C. Presented at: Association for Behavioral and Cognitive Therapies Annual Convention; 2011 Nov 10; Toronto, Canada.
266. Chan K, Groessl EJ, Hanchate AD, Clark JA, Asch SM, Gifford AL, Ho SB. Anticipating the Clinical Impact of Direct Antiviral Agent (DAA) therapy for Hepatitis C infection in the Veterans Affairs Healthcare System. Paper presented at: American Association for the Study of Liver Diseases Annual Meeting; 2011 Nov 5; San Francisco, CA.
267. Chan K, Groessl EJ, Hanchate AD, Ho SB. Potential Costs Associated with New Direct-Antiviral Agent (DAA) therapy for untreated Chronic Hepatitis C genotype 1 infection in the Veterans Health Administration. Paper presented at: International Society for Pharmacoeconomics and Outcomes Research Western Pharmacoeconomics Biennial Conference; 2011 Nov 5; Madrid, Spain.
268. Gifford AL, Asch S, Williams S, Hanchate A. Cost of Caring for Patients with Hepatitis C (HCV) in the US Department of Veterans Affairs (VA) Healthcare System. Poster session presented at: American Association for the Study of Liver Diseases Annual Meeting; 2011 Nov 5; San Francisco, CA.
269. Chan K, Lai MN, Groessl E, Hanchate A, Hernandez L, Wong J, Clark J, Asch S, Gifford A, Ho SB. Long term Clinical Impact of Direct Antiviral Agent (DAA) therapy for untreated Chronic Hepatitis C genotype 1 infection in the Veterans Health Administration. Presented at: American Association for the Study of Liver Diseases Annual Meeting; 2011 Nov 4; San Francisco, CA.
270. Chan K, Lai MN, Groessl E, Hanchate A, Hernandez L, Wong J, Clark J, Asch S, Gifford A, Ho SB. Long term Clinical Impact of Direct Antiviral Agent (DAA) therapy for untreated Chronic Hepatitis C genotype 1 infection in the Veterans Health Administration. [Abstract]. Hepatology. 2011 Nov 1; 54(S1):437A.
271. Chan K, Lai MN, Groessl EJ, Hanchate A, Hernandez A, Wong JB, Clark JA, Asch SM, Gifford AL, Ho S. Potential Costs Associated with New Direct Acting Antiviral (DAAs) Therapy for Untreated Chronic Hepatitis C Genotype 1 Infection in the Veterans Health Administration. [Abstract]. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 2011 Nov 1; 14(7):A269-A270.
272. Tyson GL, Duan Z, Kramer JR, Davila JA, Richardson PA, El-Serag HB. Level of a-fetoprotein predicts mortality among patients with hepatitis C-related hepatocellular carcinoma. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2011 Nov 1; 9(11):989-94.
273. Freiberg MS, Chang CC, Skanderson M, McGinnis K, Kuller LH, Kraemer KL, Rimland D, Goetz MB, Butt AA, Rodriguez Barradas MC, Gibert C, Leaf D, Brown ST, Samet J, Kazis L, Bryant K, Justice AC, Veterans Aging Cohort Study. The risk of incident coronary heart disease among veterans with and without HIV and hepatitis C. Circulation. Cardiovascular quality and outcomes. 2011 Jul 1; 4(4):425-32.
274. White DL, Richardson PA, Al-Saadi M, Fitzgerald SJ, Green L, Amaratunge C, Anand M, El-Serag HB. Dietary history and physical activity and risk of advanced liver disease in veterans with chronic hepatitis C infection. Digestive diseases and sciences. 2011 Jun 1; 56(6):1835-47.
275. Kanwal F, Hoang T, Kramer JR, Chrusciel R, Asch SN, El-Serag H, Asch SM. Specialty evaluation in patients with chronic hepatitis C virus infections - Role of patient versus non-patient factors. Poster session presented at: Digestive Disease Week Annual Meeting; 2011 May 7; Chicago, IL.
276. Kanwal F, Hoang T, Kramer JR, Chrusciel T, El-Serag HB, Eisen S, Dominitz JA, Asch SM. Linking quality of hepatitis C virus (HCV) care to treatment and virologic response. Paper presented at: Digestive Disease Week Annual Meeting; 2011 May 7; Chicago, IL.
277. Kramer JR, Davila JA, Duan Z, Richardson PA, Kanwal F, El-Serag H. Antiviral treatment for hepatitis C virus is associated with a reduced risk of hepatocellular carcinoma in a national cohort of US Veterans. Paper presented at: Digestive Disease Week Annual Meeting; 2011 May 7; Chicago, IL.
278. Kramer JR, Kanwal F, Mei M, Giordano TP, El-Serag H. Effectiveness of hepatitis C virus (HCV) antiviral treatment in Veterans with HIV-HCV coinfection. Paper presented at: Digestive Disease Week Annual Meeting; 2011 May 7; Chicago, IL.
279. Tyson GL, Kramer JR, Davila JA, Duan Z, Richardson PA, El-Serag HB. Alpha-fetoprotein levels are predictive of survival in hepatitis C-related hepatocellular carcinoma in United States Veterans cohort. Paper presented at: Digestive Disease Week Annual Meeting; 2011 May 7; Chicago, IL.
280. White D, Tavakoli-Tabasi S, Kuzniarek J, Pascua R, Ramsey DJ, Francis J, El-Serag HB. High total serum testosterone is associated with increased risk of advance hepatic fibrosis and inflammatory activity in male Veterans with chronic hepatitis C. Poster session presented at: Digestive Disease Week Annual Meeting; 2011 May 7; Chicago, IL.
281. Gifford AL, Drainoni M, Koppelman E, Clark JA. Patient narratives of their experiences and motivations going through hepatitis C (HCV) drug treatment. Poster session presented at: Society of General Internal Medicine Annual Meeting; 2011 May 4; Phoenix, AZ.
282. Groessl EJ, Weingart KR, Gifford AL, Asch SM, Ho SB. Development of the hepatitis C self-management program. Patient education and counseling. 2011 May 1; 83(2):252-5.
283. Groessl EJ, Weingart KR, Stepnowsky CJ, Gifford AL, Asch SM, Ho SB. The hepatitis C self-management programme: a randomized controlled trial. Journal of Viral Hepatitis. 2011 May 1; 18(5):358-68.
284. Oser ML, Cucciare MA, McKellar JD, Weingardt KR. Hazardous Alcohol Use among Veterans with Hepatitis C: Alcohol-related Coping, Consequences, and Confidence to Change. Paper presented at: Society of Behavioral Medicine Annual Meeting and Scientific Sessions; 2011 Apr 30; Washington, DC.
285. Kanwal F, Hoang T, Kramer JR, Asch SM, Goetz MB, Zeringue A, Richardson P, El-Serag HB. Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection. Gastroenterology. 2011 Apr 1; 140(4):1182-1188.e1.
286. Kramer JR, Kanwal F, Richardson P, Giordano TP, Petersen LA, El-Serag HB. Importance of patient, provider, and facility predictors of hepatitis C virus treatment in veterans: a national study. The American journal of gastroenterology. 2011 Mar 1; 106(3):483-91.
287. Stepanova M, Kanwal F, El-Serag HB, Younossi ZM. Insurance status and treatment candidacy of hepatitis C patients: analysis of population-based data from the United States. Hepatology (Baltimore, Md.). 2011 Mar 1; 53(3):737-45.
288. Rongey CA, Connors E, Monto A, Asch S, Knight SJ. Improving access to liver care among urban poor and rural Veterans with Hepatitis C associated liver disease: A Conceptual Framework. Poster session presented at: VA HSR&D National Meeting; 2011 Feb 17; National Harbor, MD.
289. Rongey CA, Hamilton N, Asch S, Knight SJ. Impaired access to specialty care among rural Veterans with Hepatitis C. Poster session presented at: VA HSR&D National Meeting; 2011 Feb 17; National Harbor, MD.
290. Davila JA, Henderson L, Kramer JR, Kanwal F, Richardson PA, Duan Z, El-Serag HB. Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus-infected veterans in the United States. Annals of internal medicine. 2011 Jan 18; 154(2):85-93.
291. Beste LA, Ioannou GN, Larson MS, Chapko M, Dominitz JA. Predictors of early treatment discontinuation among patients with genotype 1 hepatitis C and implications for viral eradication. Clinical Gastroenterology and Hepatology. 2010 Nov 1; 8(11):972-8.
292. Jacobson IM, Davis GL, El-Serag H, Negro F, Trépo C. Prevalence and challenges of liver diseases in patients with chronic hepatitis C virus infection. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2010 Nov 1; 8(11):924-33; quiz e117.
293. Singal AG, Waljee AK, Shiffman M, Bacon BR, Schoenfeld PS. Meta-analysis: re-treatment of genotype I hepatitis C nonresponders and relapsers after failing interferon and ribavirin combination therapy. Alimentary pharmacology & therapeutics. 2010 Oct 1; 32(8):969-83.
294. Kanwal F, Schnitzler MS, Bacon BR, Hoang T, Buchanan PM, Asch SM. Quality of care in patients with chronic hepatitis C virus infection: a cohort study. Annals of internal medicine. 2010 Aug 17; 153(4):231-9.
295. Kanwal F, Hoang T, Asch SM, Kramer JR, Zeringue AL, El-Serag HB. Over-utilization of hepatitis C antibody testing and its impact on the quality of care in patients with chronic hepatitis C virus infection. Poster session presented at: Digestive Disease Week Annual Meeting; 2010 May 1; New Orleans, LA.
296. Singal AG, Volk ML, Jensen D, Di Bisceglie AM, Schoenfeld PS. A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Clinical Gastroenterology and Hepatology. 2010 Mar 1; 8(3):280-8, 288.e1.
297. Chapko MK, Yee HS, Monto A, Dominitz JA. Cost-effectiveness of hepatitis A vaccination for individuals with chronic hepatitis C. Vaccine. 2010 Feb 17; 28(7):1726-31.
298. Butt AA, McGinnis KA, Skanderson M, Justice AC. Hepatitis C treatment completion rates in routine clinical care. Liver International : Official Journal of The International Association For The Study of The Liver. 2010 Feb 1; 30(2):240-50.
299. Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology. 2010 Feb 1; 138(2):513-21, 521.e1-6.
300. Fischer MJ, Wyatt CM, Gordon K, Gibert CL, Brown ST, Rimland D, Rodriguez-Barradas MC, Justice AC, Parikh CR, VACS Project Team. Hepatitis C and the risk of kidney disease and mortality in veterans with HIV. Journal of acquired immune deficiency syndromes. 2010 Feb 1; 53(2):222-6.
301. Kramer JR, Kanwal F, Giordano TP, Richardson P, Petersen LA, El-Serag HB. Patient, provider, and facility predictors of HCV antiviral treatment among US veterans with chronic hepatitis C infection. Poster session presented at: VA HSR&D Career Development Annual Meeting; 2010 Feb 1; San Francisco, CA.
302. Plebani JG, Tirado CF, Pettinati HM, Kampman KM, Volpicelli JR, Oslin DW. Combined effects of alcohol and hepatitis C: a secondary analysis of alcohol use biomarkers and high-risk behaviors from two medication trials for alcohol dependence. Addictive Behaviors. 2010 Feb 1; 35(2):123-8.
303. Fraenkel L, Chodkowski D, Lim J, Garcia-Tsao G. Patients' preferences for treatment of hepatitis C. Medical Decision Making. 2010 Jan 1; 30(1):45-57.
304. McInnes DK, Hyun JK, Trafton JA, Asch SM, Gifford AL. Program characteristics associated with testing for HIV and hepatitis C in veterans substance use disorder clinics. Psychiatric services (Washington, D.C.). 2010 Jan 1; 61(1):90-4.
305. Kramer JR, Kanwal F, Hachem C, El-Serag H. Predictors of hepatitis A and B vaccination among US veterans with chronic hepatitis C virus. Poster session presented at: American Association for the Study of Liver Diseases Annual Meeting; 2009 Oct 31; Boston, MA.
306. Groessl EJ, Weingart KR, Stepnowsky CJ, Gifford AL, Asch S, Ho SB. The Hepatitis C Self-Management Program. Paper presented at: American Association for the Study of Liver Diseases Annual Meeting; 2009 Oct 30; Boston, MA.
307. Beste LA, Straits-Troster K, Zickmund S, Larson M, Chapko M, Dominitz JA. Specialty care and education associated with greater disease-specific knowledge but not satisfaction with care for chronic hepatitis C. [Abstract]. Alimentary pharmacology & therapeutics. 2009 Aug 1; 30(3):275-82.
308. Butt AA, Xiaoqiang W, Budoff M, Leaf D, Kuller LH, Justice AC. Hepatitis C virus infection and the risk of coronary disease. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2009 Jul 15; 49(2):225-32.
309. McInnes DK, Hyun JK, Trafton JA, Asch SM, Gifford AL. Quality improvement initiatives and HIV and hepatitis C screening testing in VA substance use disorder (SUD) programs. Poster session presented at: AcademyHealth Annual Research Meeting; 2009 Jun 28; Chicago, IL.
310. Tsui JI, Whooley MA, Monto A, Seal K, Tien PC, Shlipak M. Association of hepatitis C virus seropositivity with inflammatory markers and heart failure in persons with coronary heart disease: data from the Heart and Soul study. Journal of cardiac failure. 2009 Jun 1; 15(5):451-6.
311. Kanwal F, Kramer JR, Hoang T, El-Serag H, Eisen S, Asch S. Quality of diagnosis and evaluation-related care in patients with chronic hepatitis C virus infection. Poster session presented at: Digestive Disease Week Annual Meeting; 2009 May 30; Chicago, IL.
312. Pichetshote N, Groessl E, Yee H, Ho SB. Optimizing the dose and duration of therapy for chronic hepatitis C. Gut and Liver. 2009 Mar 31; 3(1):1-13.
313. Rongey CA, Kanwal F, Hoang T, Gifford AL, Asch SM. Viral RNA testing in hepatitis C antibody-positive veterans. American journal of preventive medicine. 2009 Mar 1; 36(3):235-8.
314. Chiao EY, Engels EA, Kramer JR, Pietz K, Henderson L, Giordano TP, Landgren O. Risk of immune thrombocytopenic purpura and autoimmune hemolytic anemia among 120 908 US veterans with hepatitis C virus infection. Archives of internal medicine. 2009 Feb 23; 169(4):357-63.
315. Fischer MJ, Wyatt CM, Gordon K, Gibert C, Brown ST, Rimland D, Rodriguez-Barradas M, Justice AC, Parikh R. Hepatitis C is Associated with a High Prevalence of Chronic Kidney Disease and Mortality among Veterans with HIV. Presented at: VA HSR&D National Meeting; 2009 Feb 12; Baltimore, MD.
316. Kanwal F, Kramer JR, Hoang T, El-Serag H, Eisen S, Asch S. Quality of diagnosis and evaluation-related care in patients with chronic hepatitis C virus infection. Paper presented at: VA HSR&D National Meeting; 2009 Feb 1; Washington, DC.
317. El-Serag HB, Engels EA, Landgren O, Chiao E, Henderson L, Amaratunge HC, Giordano TP. Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: A population-based study of U.S. veterans. Hepatology. 2009 Jan 1; 49(1):116-23.
318. Himelhoch S, McCarthy JF, Ganoczy D, Medoff D, Kilbourne A, Goldberg R, Dixon L, Blow FC. Understanding associations between serious mental illness and hepatitis C virus among veterans: a national multivariate analysis. Psychosomatics. 2009 Jan 1; 50(1):30-7.
319. Clark JA, Drainoni M, Koppelman E, Gifford A. Factors Related to Hepatitis C Treatment Completion in the VHA. Paper presented at: VA QUERI National Meeting; 2008 Dec 10; Phoenix, AZ.
320. Drainoni M, Gifford AL, Koppelman E, Clark JA. Factors Associated with Hepatitis C Treatment Completion or Withdrawal among Veterans. Poster session presented at: VA QUERI National Meeting; 2008 Dec 10; Phoenix, AZ.
321. McInnes DK, Hyun JK, Trafton JA, Asch SM, Gifford AL. Initiatives to increase HIV and hepatitis C screening in VA substance use disorder programs. Poster session presented at: VA QUERI National Meeting; 2008 Dec 10; Phoenix, AZ.
322. Groessl EJ, Weingart KR, Kaplan RM, Clark JA, Gifford AL, Ho SB. Living with hepatitis C: qualitative interviews with hepatitis C-infected veterans. Journal of general internal medicine. 2008 Dec 1; 23(12):1959-65.
323. Kanwal F, Asch S, Schnitzler MS, Bacon BR. Predictors of quality care among patients with chronic hepatitis c virus infection. Paper presented at: American Association for the Study of Liver Diseases Annual Meeting; 2008 Nov 4; San Francisco, CA.
324. Hachem CY, Kramer JR, Kanwal F, El-Serag HB. Hepatitis vaccination in patients with hepatitis C: practice and validation of codes at a large Veterans Administration Medical Centre. Alimentary pharmacology & therapeutics. 2008 Nov 1; 28(9):1078-87.
325. Janke EA, McGraw S, Garcia-Tsao G, Fraenkel L. Psychosocial issues in hepatitis C: a qualitative analysis. Psychosomatics. 2008 Nov 1; 49(6):494-501.
326. Kilbourne AM, McCarthy JF, Himelhoch S, Welsh D, Hauser P, Blow FC. Guideline-concordant hepatitis C virus testing and notification among patients with and without mental disorders. General hospital psychiatry. 2008 Nov 1; 30(6):495-500.
327. White DL, Ratziu V, El-Serag HB. Hepatitis C infection and risk of diabetes: a systematic review and meta-analysis. Journal of Hepatology. 2008 Nov 1; 49(5):831-44.
328. Giordano T. The Role of Hepatitis C Virus in Waldenstrom Macroglobulinemia. Paper presented at: Waldenstrom's Macroglobulinemia International Annual Workshop; 2008 Oct 15; Stockholm, Sweden.
329. Groessl EJ, Weingart KR, Gifford AL, Asch SM, Ho SB. A self-management intervention for veterans with Hepatitis C: Preliminary Data. Paper presented at: VA QUERI Career Development Annual Meeting; 2008 Oct 1; Phoenix, AZ.
330. Kanwal, Kramer R, Giordano P, Zeringue, El-Serag B. Burden of hepatocellular cancer in a national sample of patients with chronic hepatitis C. Presented at: International Liver Cancer Association Annual Conference; 2008 Sep 5; Chicago, IL.
331. Whitehead AJ, Dobscha SK, Morasco BJ, Ruimy S, Bussell C, Hauser P. Pain, substance use disorders and opioid analgesic prescription patterns in veterans with hepatitis C. Journal of pain and symptom management. 2008 Jul 1; 36(1):39-45.
332. Kwan JW, Cronkite RC, Yiu A, Goldstein MK, Kazis L, Cheung RC. The impact of chronic hepatitis C and co-morbid illnesses on health-related quality of life. Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation. 2008 Jun 1; 17(5):715-24.
333. White DL, Ratziu , El-Serag B. Hepatitis C Infection (HCV) and Risk of Diabetes Mellitus: a systemic review and meta-analysis. Poster session presented at: Digestive Disease Week Annual Meeting; 2008 May 20; San Diego, CA.
334. Kanwal F, Kramer JR, Asch SM, Giordano TP, Zeringue A, El-Serag HB. Burden of Cirrhosis in a National Sample of Patients with Chronic Hepatitis C. Poster session presented at: Digestive Disease Week / American Gastroenterological Association Annual Conference; 2008 May 17; San Diego, CA.
335. Kanwal F, Kramer JR, Giordano TP, Zeringue A, El-Serag HB. Rate and Predictors of Erythropoietic Growth Factors Use in Chronic Hepatitis C Patients with Treatment Induced Anemia. Poster session presented at: Digestive Disease Week / American Gastroenterological Association Annual Conference; 2008 May 17; San Diego, CA.
336. Kramer JR, Kanwal F, Giordano TP, Richardson P, El-Serag HB. HCV Antiviral Treatment Among US Veterans with Chronic Hepatitis C Infection: Patient, Provider, and Facility Predictors. Poster session presented at: Digestive Disease Week / American Gastroenterological Association Annual Conference; 2008 May 17; San Diego, CA.
337. Zickmund S, Campbell S, Tirado C, Weinrieb RP. Provider communication cited as barrier to antiviral therapy for hepatitis C-infected methadone using patients. Poster session presented at: Society of General Internal Medicine Annual Meeting; 2008 Apr 9; Pittsburgh, PA.
338. Beste LA, Stein M. Redesign of chronic care for hepatitis C in a Rhode Island homeless population based on provider compliance with hepatitis C guidelines. Medicine and Health, Rhode Island. 2008 Apr 1; 91(4):116-8.
339. El-Serag H, Kramer JR. Hepatitis C infection: dying with or from the infection? Journal of Hepatology. 2008 Feb 1; 48(2):183-4.
340. Baillargeon JG, Paar DP, Wu H, Giordano TP, Murray O, Raimer BG, Avery EN, Diamond PM, Pulvino JS. Psychiatric disorders, HIV infection and HIV/hepatitis co-infection in the correctional setting. AIDS Care. 2008 Jan 1; 20(1):124-9.
341. Groom H, Dieperink E, Nelson DB, Garrard J, Johnson JR, Ewing SL, Stockley H, Durfee J, Jonk Y, Willenbring ML, Ho SB. Outcomes of a Hepatitis C screening program at a large urban VA medical center. Journal of clinical gastroenterology. 2008 Jan 1; 42(1):97-106.
342. Kanwal F, Hoang T, Spiegel BM, Eisen S, Dominitz JA, Gifford A, Goetz M, Asch SM. Predictors of treatment in patients with chronic hepatitis C infection - role of patient versus nonpatient factors. Hepatology. 2007 Dec 1; 46(6):1741-9.
343. Rowan PJ, Dunn NJ, El-Serag HB, Kunik ME. Views of hepatitis C virus patients delayed from treatment for psychiatric reasons. Journal of Viral Hepatitis. 2007 Dec 1; 14(12):883-9.
344. Seal KH, Monto A, Dove L, Shen H, Vittinghoff E, Tracy D, Miller E, Lau E, Wright TL. The association of human immunodeficiency virus infection with spontaneously resolved hepatitis C virus infection and level of viremia among injection drug users. Digestive diseases and sciences. 2007 Dec 1; 52(12):3423-30.
345. Zickmund SL, Campbell S, Tirado C, Weinrieb R. Provider communication cited as barrier to antiviral therapy for hepatitis C infected methadone users. Paper presented at: Leo H. Criep on Patient-Provider Communication Annual Symposium; 2007 Nov 15; Pittsburgh, PA.
346. Hachem, Kramer R, Kanwal , El-Serag B. The practice and validation of hepatitis vaccination in patients with hepatitis C. Presented at: American Association for the Study of Liver Diseases Annual Meeting; 2007 Nov 2; Boston, MA.
347. Brady CW, Coffman CJ, Provenzale D. Compliance with referral for hepatitis C evaluation among veterans. Journal of clinical gastroenterology. 2007 Nov 1; 41(10):927-31.
348. Kramer JR, Giordano TP, El-Serag HB. Effect of human immunodeficiency virus and antiretrovirals on outcomes of hepatitis C: a systematic review from an epidemiologic perspective. Clinical Gastroenterology and Hepatology. 2007 Nov 1; 5(11):1321-1328.e7.
349. Zickmund SL. Psychosocial issues and hepatitis C. In: Hepatitis C Choices. Oregon City, OR: Ambassador’s Care Program; 2007.
350. Zickmund SL, Brown KE, Bielefeldt K. A systematic review of provider knowledge of hepatitis C: is it enough for a complex disease? Digestive diseases and sciences. 2007 Oct 1; 52(10):2550-6.
351. Dalrymple LS, Koepsell T, Sampson J, Louie T, Dominitz JA, Young B, Kestenbaum B. Hepatitis C virus infection and the prevalence of renal insufficiency. Clinical Journal of the American Society of Nephrology. 2007 Jul 1; 2(4):715-21.
352. Tsui JI, Vittinghoff E, Shlipak MG, Bertenthal D, Inadomi J, Rodriguez RA, O'Hare AM. Association of hepatitis C seropositivity with increased risk for developing end-stage renal disease. Archives of internal medicine. 2007 Jun 25; 167(12):1271-6.
353. Heinzerling KG, Kral AH, Flynn NM, Anderson RL, Scott A, Gilbert ML, Asch SM, Bluthenthal RN. Human immunodeficiency virus and hepatitis C virus testing services at syringe exchange programs: availability and outcomes. Journal of substance abuse treatment. 2007 Jun 1; 32(4):423-9.
354. Kanwal F, Hoang T, Spiegel BM, Eisen S, Gifford A, Asch S. Predictors of Treatment Among Patients With Chronic Hepatitis C Virus Infection. Paper presented at: Digestive Disease Week / American Gastroenterological Association Annual Conference; 2007 May 20; Washington, DC.
355. Giordano TP, Henderson L, Landgren O, Chiao EY, Kramer JR, El-Serag H, Engels EA. Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus. JAMA : the journal of the American Medical Association. 2007 May 9; 297(18):2010-7.
356. Leykum LK, El-Serag HB, Cornell J, Papadopoulos KP. Screening for hepatocellular carcinoma among veterans with hepatitis C on disease stage, treatment received, and survival. Clinical Gastroenterology and Hepatology. 2007 Apr 1; 5(4):508-12.
357. Butt AA, Justice AC, Skanderson M, Rigsby MO, Good CB, Kwoh CK. Rate and predictors of treatment prescription for hepatitis C. Gut. 2007 Mar 1; 56(3):385-9.
358. Kanwal F, Hoang T, Spiegel BM, Eisen SE, Goetz M, Dominitz J, Asch SM. Quality of Care in Chronic Hepatitis C Virus (HCV) Infection. Paper presented at: VA HSR&D National Meeting; 2007 Feb 23; Arlington, VA.
359. Seal KH, Currie SL, Shen H, Anand BS, Bini EJ, Brau N, Jeffers L, Wright TL,. Hepatitis C treatment candidacy and outcomes among 4318 US veterans with chronic hepatitis C virus infection: does a history of injection drug use matter? Journal of clinical gastroenterology. 2007 Feb 1; 41(2):199-205.
360. Silberbogen AK, Janke EA, Hebenstreit C. A closer look at pain and hepatitis C: preliminary data from a veteran population. Journal of rehabilitation research and development. 2007 Jan 1; 44(2):231-44.
361. Zickmund SL. Communication, treatment decisions and stigmatization with patients suffering from hepatitis C. Paper presented at: American Liver Foundation Regional Annual Conference; 2006 Nov 15; Pittsburgh, PA.
362. Straits-Troster K, Calhoun P, Butterfield MI, Boggs C, Strauss JL. PTSD and hepatitis C infection: Association with quality of life and health behaviors. Poster session presented at: International Society for Traumatic Stress Studies Annual Meeting; 2006 Nov 1; Hollywood, CA.
363. Groessl EJ. Self-management interventions for patients with Hepatitis C. Paper presented at: University of California San Diego Department of Medicine Division of Gastroenterology Research Retreat; 2006 Oct 7; La Jolla, CA.
364. Chapko MK, Dominitz JA. Cost-effectiveness of growth factors during hepatitis C anti-viral therapy. Alimentary pharmacology & therapeutics. 2006 Oct 1; 24(7):1067-77.
365. Butt AA, Justice AC, Skanderson M, Good C, Kwoh CK. Rates and predictors of hepatitis C virus treatment in HCV-HIV-coinfected subjects. Alimentary pharmacology & therapeutics. 2006 Aug 15; 24(4):585-91.
366. Blasiole JA, Shinkunas L, Labrecque DR, Arnold RM, Zickmund SL. Mental and physical symptoms associated with lower social support for patients with hepatitis C. World journal of gastroenterology : WJG.. 2006 Aug 7; 12(29):4665-72.
367. Hwang LY, Kramer JR, Troisi C, Bull L, Grimes CZ, Lyerla R, Alter MJ. Relationship of cosmetic procedures and drug use to hepatitis C and hepatitis B virus infections in a low-risk population. Hepatology. 2006 Aug 1; 44(2):341-51.
368. Fraenkel L, McGraw S, Wongcharatrawee S, Garcia-Tsao G. Patients' experiences related to anti-viral treatment for hepatitis C. Patient education and counseling. 2006 Jul 1; 62(1):148-55.
369. Lim JK, Cronkite R, Goldstein MK, Cheung RC. The impact of chronic hepatitis C and comorbid psychiatric illnesses on health-related quality of life. Journal of clinical gastroenterology. 2006 Jul 1; 40(6):528-34.
370. Adeniyi T, Jonk Y, Johnson AK, Dieperink E, Ho SB. Direct costs of medical care for treating hepatitis C patients in a Veterans Affairs medical center. Presented at: AcademyHealth Annual Research Meeting; 2006 Jun 26; Seattle, WA.
371. Tsui JI, Vittinghoff E, Shlipak MG, O'Hare AM. Relationship between hepatitis C and chronic kidney disease: results from the Third National Health and Nutrition Examination Survey. Journal of the American Society of Nephrology : JASN. 2006 Apr 1; 17(4):1168-74.
372. Zickmund SL, Bryce CL, Blasiole JA, Shinkunas L, LaBrecque DR, Arnold RM. Majority of patients with hepatitis C express physical, mental, and social difficulties with antiviral treatment. European journal of gastroenterology & hepatology. 2006 Apr 1; 18(4):381-8.
373. Rousseau C, Ioannou G, Todd-Stenberg J, Sloan K, Dominitz J. Racial Differences in the Evaluation and Treatment of Hepatitis C: A Retrospective Cohort Study. Paper presented at: VA HSR&D National Meeting; 2006 Feb 17; Arlington, VA.
374. Butt AA, Justice AC, Skanderson M, Good CB, Kwoh CK. Rate and predictors of treatment for hepatitis C. Paper presented at: Retroviruses and Opportunistic Infections Annual Conference; 2006 Feb 1; Denver, CO.
375. Tsui JI, Pletcher MJ, Vittinghoff E, Seal K, Gonzales R. Hepatitis C and hospital outcomes in patients admitted with alcohol-related problems. Journal of Hepatology. 2006 Feb 1; 44(2):262-6.
376. Chapko MK, Dominitz JA. Cost-effectiveness of growth factors during hepatitis C antiviral therapy. Poster session presented at: National Viral Hepatitis Prevention Annual Conference; 2005 Dec 7; Washington, DC.
377. Sloan KL, Davison J, Chapko MK, Dominitz JA. Hepatitis C Seroconversion is Still Occurring in Veterans. Poster session presented at: Centers for Disease Control National Viral Hepatitis Prevention Annual Conference; 2005 Dec 7; Washington, DC.
378. Straits-Troster KA, Davison J, Kivlahan D, Curry S, Wingert M, Dierperink E, Hauser P. Improving Hepatitis C Care for Veterans: Development of a Brief Alcohol Toolkit. Paper presented at: National Viral Hepatitis Prevention Annual Conference; 2005 Dec 7; Washington, DC.
379. Fraenkel L, McGraw S, Wongcharatrawee S, Garcia-Tsao G. What do patients consider when making decisions about treatment for hepatitis C? The American journal of medicine. 2005 Dec 1; 118(12):1387-91.
380. Adeniyi T, Jonk Y, Johnson AK, Dieperink E, Ho SB. Direct costs of medical care for treating hepatitis C patients in a Veterans Affairs medical center. Presented at: American Association for the Study of Liver Diseases Annual Meeting; 2005 Nov 11; San Francisco, CA.
381. Dalrymple LS, Sampson JN, Louie TL, Young B, Kestenbaum B. A Population-Based Retrospective Cohort Study of Renal Insufficiency in Veterans with Hepatitis C Virus Exposure. Poster session presented at: American Society of Nephrology Annual Meeting; 2005 Nov 8; Philadelphia, PA.
382. Spiegel BM, Chen K, Chiou CF, Robbins S, Younossi ZM. Erythropoietic growth factors for treatment-induced anemia in hepatitis C: a cost-effectiveness analysis. Clinical Gastroenterology and Hepatology. 2005 Oct 1; 3(10):1034-42.
383. Zickmund SL. Stigmatization and barriers to hepatitis C patients. Paper presented at: American Liver Foundation Training the Trainers Annual Workshop; 2005 Oct 1; Pittsburgh, PA.
384. Rowan PJ, Al-Jurdi R, Tavakoli-Tabasi S, Kunik ME, Satrom SL, El-Serag HB. Physical and psychosocial contributors to quality of life in veterans with hepatitis C not on antiviral therapy. Journal of clinical gastroenterology. 2005 Sep 1; 39(8):731-6.
385. Brady CW, Muir AJ. HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis. Hepatology. 2005 Aug 1; 42(2):496-7; author reply 497.
386. El-Serag HB. A Patient with Chronic Hepatitis C and a Mass in the Liver. Paper presented at: Digestive Disease Week / American Gastroenterological Association Annual Conference; 2005 May 1; Chicago, IL.
387. Butt AA. Hepatitis C virus infection: the new global epidemic. Expert review of anti-infective therapy. 2005 Apr 1; 3(2):241-249.
388. Spiegel BM, Younossi ZM, Hays RD, Revicki D, Robbins S, Kanwal F. Impact of hepatitis C on health related quality of life: a systematic review and quantitative assessment. Hepatology. 2005 Apr 1; 41(4):790-800.
389. Chapko MK, Sloan KL, Davison JW, Dufour DR, Bankson DD, Rigsby M, Dominitz JA. Cost effectiveness of testing strategies for chronic hepatitis C. The American journal of gastroenterology. 2005 Mar 1; 100(3):607-15.
390. Kramer JR, Giordano TP, Souchek J, El-Serag HB. Hepatitis C coinfection increases the risk of fulminant hepatic failure in patients with HIV in the HAART era. Journal of Hepatology. 2005 Mar 1; 42(3):309-14.
391. El-Serag HB, Giordano TP, Kramer J, Richardson P, Souchek J. Survival in hepatitis C and HIV co-infection: a cohort study of hospitalized veterans. Clinical Gastroenterology and Hepatology. 2005 Feb 1; 3(2):175-83.
392. Tavakoli-Tabasi S, Rowan P, Abdul-Latif M, Kunik ME, El-Serag HB. Utility of a depression score to predict candidacy for hepatitis C virus therapy in veterans: a prospective longitudinal study. Alimentary pharmacology & therapeutics. 2005 Feb 1; 21(3):235-42.
393. Butt AA, Wagener M, Shakil AO, Ahmad J. Reasons for non-treatment of hepatitis C in veterans in care. Journal of Viral Hepatitis. 2005 Jan 1; 12(1):81-5.
394. Dominitz JA, Boyko EJ, Koepsell TD, Heagerty PJ, Maynard C, Sporleder JL, Stenhouse A, Kling MA, Hrushesky W, Zeilman C, Sontag S, Shah N, Ona F, Anand B, Subik M, Imperiale TF, Nakhle S, Ho SB, Bini EJ, Lockhart B, Ahmad J, Sasaki A, van der Linden B, Toro D, Martinez-Souss J, Huilgol V, Eisen S, Young KA. Elevated prevalence of hepatitis C infection in users of United States veterans medical centers. Hepatology. 2005 Jan 1; 41(1):88-96.
395. Kramer JR, Giordano TP, Souchek J, Richardson P, Hwang LY, El-Serag HB. The effect of HIV coinfection on the risk of cirrhosis and hepatocellular carcinoma in U.S. veterans with hepatitis C. The American journal of gastroenterology. 2005 Jan 1; 100(1):56-63.
396. Giordano TP, Kramer JR, Souchek J, Richardson P, El-Serag HB. Cirrhosis and hepatocellular carcinoma in HIV-infected veterans with and without the hepatitis C virus: a cohort study, 1992-2001. Archives of internal medicine. 2004 Nov 22; 164(21):2349-54.
397. Anderson KB, Guest JL, Rimland D. Hepatitis C virus coinfection increases mortality in HIV-infected patients in the highly active antiretroviral therapy era: data from the HIV Atlanta VA Cohort Study. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2004 Nov 15; 39(10):1507-13.
398. Vassilev ZP, Strauss SM, Astone JM, Friedmann PD, Des Jarlais DC. Provision of on-site medical care to patients with hepatitis C in drug treatment units. Journal of health care for the poor and underserved. 2004 Nov 1; 15(4):663-71.
399. Loftis JM, Socherman RE, Howell CD, Whitehead AJ, Hill JA, Dominitz JA, Hauser P. Association of interferon-alpha-induced depression and improved treatment response in patients with hepatitis C. Neuroscience Letters. 2004 Jul 22; 365(2):87-91.
400. Fultz SL, Chang CH, Skanderson M, Butt AA, Fusco GP, Dieterich DT, Becker SL, Rabeneck L, Rodriguez-Barradas M, Rigsby MO, Justice AC. Survival in patients coinfected with HIV and hepatitis C in the HAART era. Paper presented at: International AIDS Conference; 2004 Jul 9; Bangkok, Thailand.
401. Rowan PJ, Tabasi S, Abdul-Latif M, Kunik ME, El-Serag HB. Psychosocial factors are the most common contraindications for antiviral therapy at initial evaluation in veterans with chronic hepatitis C. Journal of clinical gastroenterology. 2004 Jul 1; 38(6):530-4.
402. Al Jurdi, El-Serag HB, Tavakoli Tabasi, Krishnan LL, Kunik ME. Diagnosis and treatment of depression in patients infected with hepatitis C virus. Resident and Staff Physician. 2004 Jun 1; 50(6):19-24.
403. Lin OS, Keeffe EB, Sanders GD, Owens DK. Cost-effectiveness of screening for hepatocellular carcinoma in patients with cirrhosis due to chronic hepatitis C. Alimentary pharmacology & therapeutics. 2004 Jun 1; 19(11):1159-72.
404. Chapko MK, Dominitz JA. Cost-effectiveness of growth factors during hepatitis C antiviral therapy. Paper presented at: American Association for the Study of Liver Diseases Annual Meeting; 2004 May 17; New Orleans, LA.
405. Dominitz JA, Boyko EJ, Koepsell TD, Heagerty PJ, Maynard C, Sporleder JL. Prevalence of hepatitis C infection in veterans: results of VA Cooperative Study #488. Paper presented at: American Association for the Study of Liver Diseases Annual Meeting; 2004 May 17; New Orleans, LA.
406. El-Serag HB, Giordano TP, Souchek J, Kramer JR, Richardson P. Coinfection with Hepatitis C Prolongs Survival in HIV-Infected Patients. Paper presented at: Digestive Disease Week Annual Meeting; 2004 May 15; New Orleans, LA.
407. Zickmund S, Hillis SL, Barnett MJ, Ippolito L, LaBrecque DR. Hepatitis C virus-infected patients report communication problems with physicians. Hepatology. 2004 Apr 1; 39(4):999-1007.
408. Chou R, Clark EC, Helfand M. Screening for hepatitis C virus infection: a review of the evidence for the U.S. Preventive Services Task Force. Annals of internal medicine. 2004 Mar 16; 140(6):465-79.
409. Dominitz JA, Boyko EJ, Koepsell TD, Heagerty PJ, Maynard C, Sporleder JL. Prevalence of hepatitis C infection in veterans: results of VA Cooperative Study #488. Paper presented at: VA HSR&D National Meeting; 2004 Mar 10; Washington, DC.
410. Fultz SL, Chang CH, Skanderson M, Butt AA, Fusco GP, Dieterich DT, Becker SL, Simberkoff M, Rabeneck L, Rodriguez-Barradas M, Rigsby MO, Justice AC. Survival in patients coinfected with HIV and hepatitis C using administrative data and combined cohort data from VACS and CHORUS: The role of CD4 counts. Paper presented at: International Workshop on HIV Observational Databases; 2004 Mar 9; Montreaux, Switzerland.
411. Sloan KL, Straits-Tröster KA, Dominitz JA, Kivlahan DR. Hepatitis C tested prevalence and comorbidities among veterans in the US Northwest. Journal of clinical gastroenterology. 2004 Mar 1; 38(3):279-84.
412. Butterfield MI, Bosworth HB, Stechuchak KM, Frothingham R, Bastian LA, Meador KG, Swartz M, Horner RD. Racial differences in hepatitis B and hepatitis C and associated risk behaviors in veterans with severe mental illness. Journal of the National Medical Association. 2004 Jan 1; 96(1):43-52.
413. Goodgame B, Shaheen NJ, Galanko J, El-Serag HB. The risk of end stage liver disease and hepatocellular carcinoma among persons infected with hepatitis C virus: publication bias? The American journal of gastroenterology. 2003 Nov 1; 98(11):2535-42.
414. Dominitz JA, Straits-Troster KA, Splan MF, Bush KR, Sloan KL, Lee SW, Kivlahan DR. Impact of group education on knowledge, satisfaction and quality of life among Hepatitis C patients seen by gastroenterologists. Paper presented at: American College of Gastroenterology Annual Meeting; 2003 Oct 14; Baltimore, MD.
415. Butt AA, Ahmad J, Wagener M, Singh N, Shakil AO. Risk of diabetes mellitus in hepatitis C and HIV infected patients. Paper presented at: Infectious Diseases Society of America Annual Meeting; 2003 Oct 9; San Diego, CA.
416. Zickmund S, Ho EY, Masuda M, Ippolito L, LaBrecque DR. "They treated me like a leper". Stigmatization and the quality of life of patients with hepatitis C. Journal of general internal medicine. 2003 Oct 1; 18(10):835-44.
417. Butterfield MI, Bosworth HB, Meador KG, Stechuchak KM, Essock SM, Osher FC, Goodman LA, Swanson JW, Bastian LA, Horner RD, Five-Site Health and Risk Study Research Committee. Gender differences in hepatitis C infection and risks among persons with severe mental illness. Psychiatric services (Washington, D.C.). 2003 Jun 1; 54(6):848-53.
418. Osher FC, Goldberg RW, McNary SW, Swartz MS, Essock SM, Butterfield MI, Rosenberg SD. Substance abuse and the transmission of hepatitis C among persons with severe mental illness. Psychiatric services (Washington, D.C.). 2003 Jun 1; 54(6):842-7.
419. Sloan K, Straits-Troster K, Kivlahan D, Dominitz J. Patterns in hepatitis C: prevalence and comorbidities in northwest veterans. Paper presented at: American Psychiatric Association Annual Meeting; 2003 May 1; San Francisco, CA.
420. Straits-Troster K, Dominitz J, McFall M, Sloan K. PTSD and hepatitis C comorbidity and implications for interferon-based treatments. Paper presented at: American Psychiatric Association Annual Meeting; 2003 May 1; San Francisco, CA.
421. Fultz SL, Justice AC, Butt AA, Rabeneck L, Weissman S, Rodriguez-Barradas M. Testing, referral, and treatment patterns for hepatitis C virus coinfection in a cohort of veterans with human immunodeficiency virus infection. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2003 Apr 15; 36(8):1039-46.
422. Ioannou GN, Dominitz JA, Weiss NS, Heagerty PJ, Kowdley KV. Racial differences in the relationship between hepatitis C infection and iron stores. Hepatology. 2003 Apr 1; 37(4):795-801.
423. Hsu FC, Starkebaum G, Boyko EJ, Dominitz JA. Prevalence of rheumatoid arthritis and hepatitis C in those age 60 and older in a US population based study. The Journal of rheumatology. 2003 Mar 1; 30(3):455-8.
424. Chapko M, Sloan K, Davison J, Dufour D, Bankson D, Rigsby M, Dominitz J. Evaluation of hepatitis C testing strategies using decision analysis. Paper presented at: VA HSR&D National Meeting; 2003 Feb 14; Washington, DC.
425. Butt AA, Justice AC, Fultz SL. Hepatitis C increases the risk of DM in HIV infected veterans in care. Paper presented at: Retroviruses and Opportunistic Infections Annual Conference; 2003 Feb 12; Boston, MA.
426. Fultz SL, Justice AC, Chang CH, Butt AA, Skanderson M, Rimland D. Impact of hepatitis C, HIV or both on survival in veterans in care before and after HAART. Paper presented at: VA HSR&D National Meeting; 2003 Feb 12; Washington, DC.
427. Fultz SL, Chang CH, Butt AA, Skanderson M, Rimland D, Rigsby MO, Justice AC. Impact of hepatitis C, HIV or both on survival in veterans in care before and after HAART. Paper presented at: Retroviruses and Opportunistic Infections Annual Conference; 2003 Feb 10; Boston, MA.
428. Babik JM, Holodniy M. Impact of highly active antiretroviral therapy and immunologic status on hepatitis C virus quasispecies diversity in human immunodeficiency virus/hepatitis C virus-coinfected patients. Journal of Virology. 2003 Feb 1; 77(3):1940-50.
429. Butt AA. Update on hepatitis C. Paper presented at: American Medical Women's Association Annual Congress; 2003 Jan 15; Atlanta, GA.
430. Straits-Troster K, Kivlahan D, Bush K, Splan M, Sloan K, Sporleder J, Dominitz J. Hepatitis C Virus (HCV) knowledge, health risk behaviors and interest in health services among HCV+ veterans. Annals of behavioral medicine : a publication of the Society of Behavioral Medicine. 2003 Jan 5; 25; S:129-129.
431. El-Serag HB, Anand B, Richardson P, Rabeneck L. Association between hepatitis C infection and other infectious diseases: a case for targeted screening? The American journal of gastroenterology. 2003 Jan 1; 98(1):167-74.
432. Felker BL, Sloan KL, Dominitz JA, Barnes RF. The safety of valproic acid use for patients with hepatitis C infection. The American journal of psychiatry. 2003 Jan 1; 160(1):174-8.
433. Dieperink E, Willenbring ML, Thuras P. Cortisol and depressive symptoms in hepatitis C patients treated with interferon-alpha and ribavirin. Paper presented at: American Association for the Study of Liver Diseases Annual Meeting; 2002 Dec 1; Boston, MA.
434. El-Serag HB, Hampel H, Yeh C, Rabeneck L. Extrahepatic manifestations of hepatitis C among United States male veterans. Hepatology. 2002 Dec 1; 36(6):1439-45.
435. Willenbring ML. Management of psychiatric and addictive disorders in patients with hepatitis C. Paper presented at: American Academy of Addiction Psychiatry Annual Meeting; 2002 Dec 1; Las Vegas, NV.
436. Willenbring ML, Dieperink E, Wingert M, Ho S. Integrating care for psychiatric and addictive disorders in patients with hepatitis C: A treatment manual. 2002 Dec 1.
437. El-Serag HB. Hepatocellular carcinoma and hepatitis C in the United States. Hepatology. 2002 Nov 1; 36(5 Suppl 1):S74-83.
438. Butt AA, Ahmad J, Wagener J, Shakil AO, Singh N. Reasons for non-treatment of hepatitis C in veterans in care. Paper presented at: Infectious Diseases Society of America Annual Meeting; 2002 Oct 24; Chicago, IL.
439. Butt AA. Hepatitis C information on the world wide web. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2002 Sep 15; 35(6):754-9.
440. Hassan MM, Frome A, Patt YZ, El-Serag HB. Rising prevalence of hepatitis C virus infection among patients recently diagnosed with hepatocellular carcinoma in the United States. Journal of clinical gastroenterology. 2002 Sep 1; 35(3):266-9.
441. el-Serag HB, Kunik M, Richardson P, Rabeneck L. Psychiatric disorders among veterans with hepatitis C infection. Gastroenterology. 2002 Aug 1; 123(2):476-82.
442. Fultz SL, Butt AA, Weissman S, Rabeneck L, Justice AC. Evaluation and treatment of HIV+ veterans coinfected with hepatitis C. Paper presented at: International AIDS Conference; 2002 Jul 12; Barcelona, Spain.
443. Ioannou GN, Tung BY, Kowdley KV. Iron in hepatitis C: villain or innocent bystander? Seminars in Gastrointestinal Disease. 2002 Apr 1; 13(2):95-108.
444. Fultz SL, Butt AA, Weissman S, Rabeneck L, Justice AC. Evaluation and treatment of HIV+ veterans coinfected with hepatitis C. Paper presented at: International Workshop on HIV Observational Databases; 2002 Mar 15; Sintra, Portugal.
445. Sloan K, Straits-Troster K, Dominitz J, Kivlahan D. Hepatitis C Testing in the VHA Northwest Network - Prevalence, Risk Markers & Future Recommendations. Paper presented at: VA HSR&D National Meeting; 2002 Feb 14; Washington, DC.
446. Gordon AJ, Conigliaro J, Justice AC, McGinnis KA, Kilbourne AM, Rabeneck L, Brown S. Alcohol consumption effects in HIV infected persons with hepatitis C. Paper presented at: Interscience Conference on Antimicrobial Agents and Chemotherapy / Infectious Diseases Society of America Joint Meeting; 2001 Dec 19; Chicago, IL.
447. Straits-Troster K, McFall M, Sloan K, Dominitz J, Kivlahan D. Is PTSD a risk factor for Hepatitis C infection. Paper presented at: International Society for Traumatic Stress Studies Annual Meeting; 2001 Dec 1; New Orleans, LA.
448. Lee S, Brennan J, Croghan A, Dominitz J. Impact of a patient group education model on Hepatitis C knowledge. Paper presented at: American College of Gastroenterology Annual Meeting; 2001 Oct 29; Las Vegas, NV.
449. Straits-Troster K, Calsyn D, Sloan K, Dominitz J, Kivlahan D. Hepatitis C is a new challenge for behavioral medicine. Paper presented at: Society of Behavioral Medicine Annual Meeting and Scientific Sessions; 2001 Mar 15; Seattle, WA.
450. Richardson SJ, Lopez F, Rojas S, Cho S, Holodniy M, Herndier B, Katz J. Multinodular polymyositis in a patient with human immunodeficiency and hepatitis C virus coinfection. Muscle & Nerve. 2001 Mar 1; 24(3):433-7.
451. Butterfield M, Bosworth HB, Meador KG, Stechuchak K, Bastian LA, Swanson J, Swartz MS, Horner RD, and the. Gender differences in Hepatitis C and associated risks in persons with severe mental illness. Paper presented at: VA HSR&D National Meeting; 2001 Feb 1; Washington, DC.
452. Rosenberg SD, Goodman LA, Osher FC, Swartz MS, Essock SM, Butterfield MI, Constantine NT, Wolford GL, Salyers MP. Prevalence of HIV, hepatitis B, and hepatitis C in people with severe mental illness. American journal of public health. 2001 Jan 1; 91(1):31-7.
453. Beymer C, Boyko E, Dominitz J. The association of diabetes mellitus with hepatitis C virus infection in a seroprevalence survey of the general U.S. population 1988 to 1994. Paper presented at: American Association for the Study of Liver Diseases Annual Meeting; 2000 Oct 20; Dallas, TX.
454. Dawson TM, Starkebaum G. Isolated central nervous system vasculitis associated with hepatitis C infection. The Journal of rheumatology. 1999 Oct 1; 26(10):2273-6.
455. Powell DW, Abramson BZ, Balint JA, Belle S, Bloomer JR, Diehl AK, Frakes JT, Garcia-Tsao G, Hook EW, Lusher M, Popovsky MA, Rabeneck L, Williams ALB. National Institutes of Health Consensus Statement: Management of Hepatitis C. Hepatology. 1997 Jan 1; 26:2S-10S.

Questions about the HSR website? Email the Web Team

Any health information on this website is strictly for informational purposes and is not intended as medical advice. It should not be used to diagnose or treat any condition.